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1. Introduction 
 
Phosphoinositide 3-kinases (PI3Ks) play an important role in a variety of cellular activities, 
including mitogenic signalling and cell survival, cytoskeletal remodelling, metabolic control, 
proliferation and vesicular trafficking. Consistent with their function in cell survival and growth, the 
gene for the class Iα PI3K catalytic subunit is a common site of cancer mutations. Ongoing 
structural studies of these enzymes and the complexes they make with their regulatory subunits 
have helped to clarify the mechanistic basis of this role in tumor development. The broad spectrum 
of biological activities associated with various isotypes of class I PI3Ks has led to an intense search 
for isotype-specific inhibitors as tools in mammalian cell biology and for therapeutic application. 
With the review “Targeting phosphoinositide 3-kinase—Moving towards therapy” (published at 
Biochimica et Biophysica Acta, 2007) we summarized the most important aspects of lipid kinase 
signalling in inflammation, cancer and metabolic disease, and discussed emerging strategies for 
therapeutic intervention. Last but not least, we reviewed as first the progress of >400 recent patents 
covering pharmaceutical targeting of PI3K. Due to its uniqueness, this review has been highly-cited 
within last 2 years (>100 citations in journals with good- to highest-impact factor). 
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2. Research Project 
 
The pharmaceutical development of PI3K inhibitors has made a great leap forward during the 
last 7 years as described in previous introduction chapter. Promising molecules have entered clinical 
trials for cancer therapy, inflammation and coronary heart disease. The PI3K pathway clearly 
presents both a great therapeutic opportunity and a tremendous challenge for cancer therapy. While 
inhibitor selectivity is often impressive when assessed in vitro, the in vivo selectivity, potency and 
efficacy often require further optimization. There are several small molecular weight chemical 
compounds in clinical development that target the PI3K/Akt signalling pathway for the treatment of 
cancer. These include dual PI3K-mTOR inhibitors, PI3K inhibitors, Akt inhibitors and mTOR 
complex catalytic site inhibitors. 
The goal of this work was to design and develop novel small molecular weight compounds able 
to selectively inhibit individual PI3K isoforms or PI3K-related proteins, with the aim to 
systematically validate these lipid kinases as drug targets in cancer and to proof the anti-cancer 
potential of novel compounds. Many of the PI3K inhibitors that are currently in clinical 
development inhibit all of the catalytic subunit isoforms of class IA PI3Ks (p110α, p110β, p110δ) 
whereas others inhibit only individual isoforms. It was not clear at the beginning of the project 
whether or not targeting: i) single PI3K isoform, ii) all class I PI3K isoforms, iii) PI3K/mTOR or 
iv) mTOR will be successful in cancer therapy. To contribute to the answer of this molecular 
oncology question, we identified the compounds under development by pharmaceutical industry 
through the intensive patent search and synthesized dual pan-PI3K/mTOR inhibitor PI-103 
(Intelectual Property (IP) of Roche/Piramed, Switzerland/UK) and selective pan-PI3Ka inhibitor 
ZSTK474 (IP of Zenyaku, Japan) in a multi-gram scale and successfully proved their anti-tumour 
activity in vitro and in vivo as well as their selectivity effect on melanomab cancer. Additionally we 
did an in-depth analysis of >400 patents (~100-300 pages per patent!) with the aim to get an 
overview of chemical compounds able to inhibit PI3Ks. Representatives from different chemical 
classes of PI3K inhibitors were selected and compounds from each class were synthesized and 
activity against the class I PI3Ks measured in vitro. Based on this initial screen, a subset 
representing the most potent and selective agents was selected for further characterization. For most 
chemotypes, a negative control compound, inactive against all PI3Ks tested, was also synthesized. 
Through the further synthetic efforts, biological and X-ray characterization we could successfully 
                                                 
a pan-PI3K inhibitor means that such compound is able to inhibit class I PI3K family (PI3Kα, PI3Kβ, PI3K, PI3Kδ) 
but not mTOR, which is a PI3K-related protein with similar catalytic function and structural homology. 
b Melanoma is a malignant tumor of melanocytes, which are found predominantly in skin but also in the bowel and the 
eye. It is one of the less common types of skin cancer but causes the majority (75%) of skin cancer related deaths 
(http://www.aafp.org/afp/20000715/357.html). 
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obtain the binding mode of many compounds protected by pharmaceutical industry. The gained 
informations from such unique structure-activity-relationship studies we could successfully apply 
by developing novel drug discovery strategy, which we called matrix-template strategy, where 
modern medicinal chemistry techniques were combined with the aim to get novel highly active 
compounds which should close the gaps in knowledge of the specific function of the different PI3K 
isoforms. 
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3. Discussion and Results 
 
3.1. Development of Pyridinylfuropyrimidine Derivatives for Cancer Therapy 
 
Before the first promising results of pyridinylfuropyrimidine lipid kinase inhibitor PI-103 as an 
anti-cancer agent were published in 2006 [1], [2] we started to encode from Japanese the synthesis 
of pyridinylfuropyrimidine derivatives from the patent WO0183456A1 of the Japanese 
pharmaceutical company “Yamanouchi”, with the aim to test few selected compounds against 
melanoma cancer, where the PI3K pathway is constitutively elevated. One of the selected 
compounds from the Yamanouchi patent was 3-(4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-
2-yl)phenol (today known as PI-103), which we selected according to the previous published results 
from 2005 by Condliffe and colleagues, where the bioisosterc of PI-103, compound YM-024 or N-
(3-(4-morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenyl)acetamide (Figure 1) was 
identified as a class I PI3K inhibitor by studing which PI3K isoforms are responsible for 
modulating neutrophil responsiveness to infection and inflammation [3].  
                                                 
c In medicinal chemistry, bioisosteres are substituents or groups with similar physical or chemical properties that impart 
similar biological properties to a chemical compound. In drug design, the purpose of exchanging one bioisostere for 
another is to enhance the desired biological or physical properties of a compound without making significant changes in 
chemical structure. The main use of this term and it techniques are related to pharmaceutical sciences. 
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Figure 1. Yamanouchi patent WO0183456A1 (left) and selected pyridinylfuropyrimidine derivatives, compounds PI-
103 and YM-024 (right), which were synthesized with the aim to explore their anti-cancer activity and their selectivity 
against class I PI3K isoforms.  
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3.1.1. Synthesis of Pyridinylfuropyrimidine Derivative PI-103 
 
The commercial available starting material 2-chloropyridine-3-carbonitrile (1) was treated with 
ethyl glycolate under basic conditions in the presence of 3-methylbutanol, where the 
aminofuropyridine 2 (AS3)d was obtained. Amide formation of 2 with 3-methoxybenzoyl chloride 
yielded the furopyridine 3 (AS7). Further ester hydrolysis of 3 and directly amide formation with 
methanolic ammonia yielded the amide 4, which was cyclizated under basic conditions in ethanol 
after Mhaske and Argade [4] to the pyrimidinone 5 (AS18). Cleavage of the methyl group under 
acidic conditions, and further protection of the phenol group with acetic anhydride yielded the 
pyrimidinone 7 (AS21). Further treatment with phosphorus oxychloride (POCl3) gave the 
chlorinated pyrimidine 8 (AS24), which was substituted on the chlorine position with morpholine to 
yield the desired compound 9 (PI-103). The same synthetic route could be successfully applied to 
produce PI-103 in a multi-gram scale (Figure 2) with the aim to explore its activity on in vivo 
cancer models, such as melanoma mice models. 
                                                 
d Original codes of the relevant compounds are presented in brackets. 
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Scheme 1. 
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aReagents and conditions: (a) ethyl glycolate (1.1 eq.), Na2CO3 (2.0 eq.), 3-methylbutanol, reflux, 72 h,
31%; (b) 3-methoxybenzoyl chloride (1.1 eq.), Et3N (1.1 eq.), CH2Cl2, room temp., 28 h, 86%; (c)
NH3(sat.), MeOH, room temp., 4 h, 100%; (d) 5% NaOH(aq.) (10 eq.), EtOH, reflux, 1 h, 90%; (e)
AcOH(conc.), HBr(conc.), reflux, 8 h, 100%; (f) Ac2O (~100 eq.), Et3N (1.6 eq.), reflux, 1 h, 42%;  (g) POCl3 
(100 eq.), reflux, 3 h,100%; (h) morpholine (2.2-3.5 eq.), n-butanol, 105 °C, 4 h, 40%.
a) b)
c)
d)e)
f)
g) h)
1 2
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Figure 2. Pressure autoclave with glass tube magnetic drive was used for the multigram-scale synthesis of the 
inhibitor PI-103. 
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3.1.2. Biological Activity of PI-103 and its Mechanism of Action 
 
A key challenge in targeting the PI3K family with small molecular weight compounds is to 
understand how individual PI3K isoforms control normal physiology, as this defines the therapeutic 
window for targeting a specific isoform. Cell-permeable small molecule inhibitors make it possible 
to directly assess the phenotypic consequences of inhibiting a kinase with a drug in a 
physiologically relevant model system.  
After successful synthesis of PI-103 its biological activity in vitro for each class I PI3K isoform 
and in different cancer cell lines was proofed. A negative control compound 16, inactive in tested 
cells, was also synthesized that differs from the active inhibitor by a single atom substitution 
(morpholino oxygen was exchanged with the piperidino carbon) (Table 1).  
 
Table 1. 
N
N
O
N
R1
OH
 
In cell inhibition 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++++ ++++ 
9 (PI-103) 
N
O
*  
20 
+++ +++ 
- - 
16 
N
*  
ND 
- - 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
 
At the same time the researcher from the University of San Francisko from the competitive lab 
of Prof. Kevan Shokat published a respectfull paper, where they described a similar synthesis of PI-
103 (milligram-scale synthesis) and their observation that PI-103 is the first potent, synthetic 
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mTORe inhibitor [1]. Additionally the authors found that PI-103 is able to target not only class I 
PI3K isoforms and mTOR but also DNA-PKf with low nanomolar activity, because all three target 
enzymes share similar sequence identity. To define targets critical for cancers driven by activation 
of PI3K, Shokat and colleagues screened a panel of potent and structurally divers drug-like 
molecules that target this enzyme family and found that only compound PI-103 effected 
proliferative arrest in gliomag cells, despite the ability of many other compounds to block PI3K 
signalling through its downstream effector, Akt (serine/threonine kinase). The unique cellular 
activity of PI-103 was traced directly to its dual inhibition of PI3K and mTOR.  
To proof the anti-tumor effect of PI-103 and its dual nature inhibition we constructed an 
aggressive B16 mouse melanoma tumor model and administered PI-103 with no obvious toxicity. 
The anti-tumor effect of PI-103 was compared with the orraly available and also dual PI3K/mTOR 
inhibitors from pharmaceutical company “Novartis” (Basel, Switzerland), compounds NVP-
BAG956, NVP-BBD130, and NVP-BEZ235 (Figure 3). The anti-tumor effect of dual inhibitors 
was compared with the anti-tumor effect of compound ZSTK474 (IP of pharmaceutical company 
“Zenyaku”, Japan) (Figure 3), which selectively inhibits class I PI3Ks but not mTOR. In 
conclusion, compounds targeting PI3K and mTOR simultaneously were advantageous to attenuate 
melanoma growth and they develop their potential by targeting tumor growth directly and indirectly 
via their interference with angiogenesis [5]. Based on these results, we successfully presented that 
NVP-BEZ235, which has entered phase I/II clinical trials in patients with advanced solid tumors, 
has a potential in metastatic melanoma therapy [6]. Although PI-103 did not enter clinical trials due 
to its poor water solubility and therefore not oral application and its rapid in vivo metabolism [7], 
we showed that this compound has the potential to be very useful as an experimental compound in 
cancer research in the future, last but not least due to availability of pharmacological data. 
Moreover, PI-103 represents a lead for further optimization of this novel class of targeted molecular 
cancer therapeutic. 
                                                 
e mTOR or mammalian target of rapamycine is a serine/threonine protein kinase that regulates many cellular processes. 
It is a PI3K-related protein with similar catalytic activity and structural homology; mTOR is important drug target for 
cancer therapy. 
f DNA-PK is DNA dependent protein kinase important for DNA repair. 
g A glioma is a type of tumor that starts in the brain or spine. It is called a glioma because it arises from glial cells. The 
most common site of gliomas is the brain. 
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N
N
N
ON
N
NVP-BEZ235
(Novartis)
Imidazo[4,5-c]quinolin core
NN
N N
N
N
O
NO
F
F
ZSTK474
(Zenyaku)
1,3,5-triazine core  
Figure 3. Orally available PI3K/mTOR inhibitor NVP-BEZ235 (in clinical phase I/II) and selective class I PI3K 
inhibitor ZSTK474. Both molecules were used to study their anti-melanoma potential, which was compared with the 
anti-cancer potential of PI-103. 
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3.2. Identification of Novel Hits by Matrix-Template Strategy 
 
It has been shown that marketed drugs are highly similar to the leadsh from which they were 
derived [8]. Thus, the quality of lead classes available to medicinal chemists is very important for 
discovering best-in-class medicines. This makes lead generation a crucial step in the drug discovery 
process. Over the past decade, high-throughput screening (HTSi) has become the major paradigm 
for hit or lead discovery in pharmaceutical industry. However, in many cases, HTS either fails to 
deliver any promising hit or the identified hits cannot be turned into lead compounds with desirable 
in vitro potency and selectivity. Last but not least, there are still particular cases for which the set-
up of the screen is expensive and time-consuming. In addition, in silico methods and fragment-
based lead discovery can also be applied, either as an alternative to HTS, or as additional lead 
sourse when HTS hits are inadequeate to initiate a medicinal chemistry program. The most widely 
applied techniques used in the primary screening of fragment-like molecules include NMR [9], MS 
[10] and X-ray [11], which are limited related to target size, tendency to form crystals, or need for 
mutations or labelling. Once the hits are confirmed, the selection process begins for hit-to-lead 
follow up. For hits from HTS, selectivity, chemical tractabilityj, binding mechanism, 
pharmacokinetic properties and patentability are usually viewed as more significant that the actual 
potency of the confirmed hits.  
Here we present an alternative knowledge-based hit and lead strategy, which in case of 
PI3K/mTOR inhibitors demonstrated to be cost-friendly and highly efficient. With the aim to 
explore the chemical space of compounds, which are able to inhibit the activity of lipid kinases we 
did an in-depth analysis of >400 patents. Representatives from different chemical classes of lipid 
kinase inhibitors were selected and compounds from each class were synthesized. In vitro activity 
against PI3Kα as well as cellular activity of synthesized compounds were measured (Figure 4). For 
most chemotypes, a negative control compound, inactive against PI3Ks, was also synthesized. 
Based on this initial screen and known SARk data from the literature (for summarized literature data 
see our published review [12]), a subset representing the most potent and selective agents was 
selected for further characterization step that we called fragment validation step. In this step we 
examined which structural fragments of the known PI3K inhibitors are significant for biological 
                                                 
h LEAD is “a prototypical chemical structure or series of structures that demonstrate activity and selectivity in a 
pharmacological or biochemically relevant screen. This forms the basis for a focused medicinal chemistry effort for lead 
optimization and development with the goal of identifying a clinical candidate. A distinct lead series has a unique core 
structure and the ability to be patented separately” (Bleicher et al., Nat Rev Drug Discov, 2003).  
i HIGH-THROUGHPUT SCREENING is screening (of a compound collection) to identify hits in an in vitro assay 
usually performed robotically in 384-well microtitre plates. 
j CHEMICAL TRACTABILITY is suitability of a compound for chemical modification. 
k STRUCTURE-ACTIVITY RELATIONSHIP (SAR) is the consistent correlation of structural features or groups with 
the biological activity of compounds in a given biological assay (Bleicher et al., Nat Rev Drug Discov, 2003). 
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activity and which could serve for further chemical optimization. For this purpose, several 
derivatives of known PI3K inhibitors were synthesized, and the nature of their interactions with the 
target protein was analyzed by different cellular assays, X-ray and in silico experiments (Figure 5).  
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Figure 4. Structures of representative compounds from twelve classes of lipid kinase inhibitors that were selected from 
the public domain and tested in vitro against PI3Kα and in cell. The core chemotype is colored blue.  
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Figure 5. In the fragment validation step we examined, which structural fragments of the known PI3K inhibitors are 
significant for biological activity, and which could serve for further chemical optimization. For this purpose, we 
modified all possible positions around the molecular scaffold and synthesized several analogues of the known PI3K 
inhibitors, which activity and the binding mode was further analyzed by different cellular assays, X-ray and in silico 
experiments. 
 
According to our results from different cellular and in vitro assays (e.g. competitive experiments 
with covalent natural inhibitor wortmannin, which binds covalently to a lysine in the ATP-binding 
pocket), X-ray crystal structures and published literature results, most PI3K inhibitors that have 
been developed for pharmaceutical applications work by competing with ATP binding. Similar to 
protein kinases, the ATP-binding site of PI3K is located in a cleft formatted by the N- and the C-
terminal lobe of the catalytic domain [12], [13], [14]. The protein backbone and amino acid residues 
Met-804, Trp-812, Glu-880, Val-882 and Met-953 of PI3K define a unique surface lining the ATP 
binding site, which provides more free space than typical protein kinases [14]. The crystal structures 
of the inhibitor•PI3K complexes show that each of the inhibitors binds in the ATP-binding site, 
with one ring system partially overlapping and coplanar with the space occupied by the adenine 
moiety of ATP [12], [13]. All of the inhibitors have a hydrogen bond acceptor in a position 
equivalent to N1 of ATP. This is a feature that seems to be conserved in all kinase-inhibitor 
complexes [15]. This interaction in PI3K involves the backbone of Val-882 and the morpholino 
oxygen of PI3K inhibitors such as LY294002 [13], PI-103 [1], and ZSTK474 (see the X-ray data 
obtained by Cmiljanovic et al.), and GDC-0941 [16] (for chemical structures of these compounds 
see Figure 6 and text below). Removal of the oxygen from a single morpholine resulted in a lost of 
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inhibitor activity (Figure 5). Additionally, known from the public domain and validated by our own 
research, morpholine-containing PI3K inhibitors are able to specifically target whether an 
individual PI3K isoform (compound TGX-221 targets selectively PI3Kβ isoform [17], Figure 6) or 
class I PI3Ks (p110α, p110β, p110 and p110δ) without additional mTOR activity (compound 
ZSTK474 [18]) or mTORl without affecting the PI3K activity (compound WYE-354 [19] and 
compound KU-0063794 [20], Figure 6).  
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Figure 6. Representatives of morpholine-containing lipid kinase inhibitors known from the public domain. PI-103 
targets with low-nanomolar activity the whole class I PI3Ks (isoforms p110α, p110β, p110 and p110δ) as well as 
mTOR and DNA-PK (DNA dependent kinase) [1]. GDC-0941 targets with low-nanomolar activity class I PI3Ks and 
with sub-nanomolar activity mTOR [16]. TGX-221 is able to inhibit selectively the PI3K isoform in vitro [17]. 
LY294002 is a broad lipid kinase inhibitor [12]. ZSTK474 is a selective class I PI3K inhibitor [18] without mTOR 
activity, and WYE-354 [19] and KU-0063794 [20] are selective mTOR inhibitors. 
 
Because of available structural and promising biological data regarding target selectivity of 
morpholine-containing inhibitors as well as low cost availability of their building blocks, we used 
                                                 
l Targeting of mTOR includes complexes mTORC1 and mTORC2; mTORC1 is controlling the activation of S6K1 
(ribosomal protein S6 kinase) and 4E-BP1 (so-called 4E-binding protein) and therefore ribosome biogenesis and 
translation. mTORC2 is making a positive feedback loop to phosphorylate PKB/Akt on Ser473. It is assumed that only 
mTORC1 is integrating nutrient and energy signals. 
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the morpholine pharmacophorem as a filter to select the relevant compounds from the patent 
chemical space for their further optimizations. Target selectivity, cellular activity measured by 
phosphoPKB-PKBn detection and in vitro activity against PI3Kαo activity were used as next filter 
criteria to eliminate specific scaffolds and their representatives from the chemical library (Figure 7).  
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Figure 7. Filtering the morpholine-containing PI3K inhibitors according to their selectivity. Compound LY294002 is a 
broad range PI3K inhibitor with unwished toxicological effects [12], TGX-221 is selective inhibitor of PI3Kβ, which 
has no proven relevance in cancer therapy, and KU-55933 is a selective ATM (PI3K-related protein kinase) inhibitor. 
For PI-103, 15e and ZSTK474 a high anti-cancer potential was proofed [5]. 
 
                                                 
m The IUPAC definition of a pharmacophore is "an ensemble of steric and electronic features that is necessary to ensure 
the optimal supramolecular interactions with a specific biological target and to trigger (or block) its biological 
response” (Wermuth, C.G., et al., Pure Appl. Chem., 1998).  
n PKB also known as Akt is a downstream effector of PI3K in so-called PI3K/Akt signalling pathway. 
o PI3Kα is the promising drug target in cancer. 
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Due to the importance of selective targeting of: i) mTOR, ii) PI3Kα, iii) class I PI3K or iv) class I 
PI3K/mTOR for cancer therapy, we wondered if we could design novel compounds with concerted 
selectivity by exploiting the structural properties of the known inhibitors with well-characterized 
selectivity profiles. More precisely, we aimed to explore how the specific changes in a chemical 
structure of small molecular weight lipid kinase inhibitors, could influence their selectivity within 
the same target family. For example, PI-103 (Figure 7) targets PI3K and mTOR at the same time, 
while ZSTK474 (Figure 7) is a pan-PI3K inhibitor without mTOR activity. We assumed that 
movement from ZSTK474 to PI-103 through the insufficient explored chemical space would lead 
us to novel molecules with refined target selectivity. 
With the aim to systematically explore the previous described ideas and to close the gaps in 
knowledge of the specific function of different PI3K isoforms, we made a library of ~300 drug-like 
compounds, which were designed by applying specific combination of common medicinal 
chemistry methods such as scaffold hybridizationp (also called scaffold morphing) and scaffold 
hopping on compounds selected in previous described steps. We firstly applied scaffold hybriding 
and scaffold hopping on ten different morpholin-containing compounds with the most active 
cellular properties and different selectivites. For example, the molecular fragments of compound PI-
103, which is a PI3K/mTOR inhibitor, were crossed with the fragments of selective pan-PI3K 
compound ZSTK474 (Figure 8). The activity and selectivity of novel hybrid- and hopping-
molecules was systematically investigated. 
                                                 
p For better understanding of the chemistry done for this project, the term “hybrid” should be explained. According to 
the Oxford English Dictionary the word “hybrid” is derived from Latin hybrida, meaning the “offspring of a tame sow 
and a wild boar”, “child of a freeman and slave”, etc. In general usage, “hybrid” is a thing made by combining two 
different elements, the offspring of two plants or animals of different species or varieties, such as a mule. 
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Figure 8. Presented is a strategy where the fragments of the known biologically active chemical compounds are crossed 
between each other, with the aim to obtain novel so-called hybrid-molecules. This offers the potential to modify existing 
leads in terms of selectivity, pharmacokinetic properties or side-effect profile. Novel hybrid molecules can be crossed 
with compounds obtained by crossing of two other PI3K inhibitors, with the aim to gain second generation hybrid 
molecules. In this example the chemical space of molecules PI-103 and ZSTK474 was rationally extended by applying 
scaffold hybriding and scaffold hopping strategies at the same time to provide novel molecules that are not covered by 
pharmaceutical industry and for which interesting biological properties where obtained. In comparison with the 
medicinal chemistry examples from the literature, where whether hybriding or hopping was obtained on a certain single 
scaffold, we obtained both strategies in a combinatorial way on several different scaffolds (see Matrix table, Figure 10). 
 
In comparison with the known examples from the public domain, where only one scaffold 
relevant for a certain project was whether hybrided or hopped, we performed combinatorial 
optimization of our preselected molecules by parallel applying of scaffold hybriding and scaffold 
hopping strategies. Designed molecules were successfully synthesized and their activity was 
measured in vitro against PI3Kα and mTOR and in cell. Additionally, in close collaboration with 
computational scientists from the research group of Prof. Marketa Zvelebil (London Cancer 
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Research Institute) all molecules were dockedq into the available crystal structures of PI3Kα and 
PI3K isoforms and modelled structure of mTOR to explore the binding mode orientations of the 
docked ligands and their binding energies. Moreover, the first obtained in silico results were 
optimized with the results obtained from synthesis, X-ray and biological experiments, and were 
used as training sets for later experiments, where the docking of new molecules was successfully 
automated. In close collaboration with crystallographists from the research group of Prof. Roger 
Williams (Cambridge University, MRC Laboratory of Molecular Biology) an X-ray analysis of the 
most potent inhibitors was successfully accomplished. Such in-depth analysis led us to the fact that 
only morpholine moiety of the tested compounds is able to recognize the prominent valine entity 
making a key hydrogen bond; non-formation of the key hydrogen bond led to total inactivity of the 
relevant compounds. This criteria was used for the next filtering step, where all candidates without 
morpholine fragment were eliminated to avoid the synthesis; for example the PI-103 hybrid with the 
fragment sequence AEC (on the mid-left side of the Figure 8) did not fulfil the morpholine criteria 
and was eliminated; to confirm the quality of such morpholin-filter this compound and several 
analog compounds were synthesized and biologically characterized; they were inactive in vitro and 
in cell (for experimental results see the chapter 4 “Chemistry and Biology”). 
The previous results led us to a more focused library of 78 compounds that we called matrix-
template library. Here we hopped from one into another morpholine-containing scaffold (see the 
first column from the left of the matrix table, Figure 10) and all these scaffolds were hybrided with 
appropriate fragments that we called “hybrid fragments” (see the first row at the top of the matrix 
table, Figure 10). Hybrid fragments were selected from the literature and patent domain. We 
supposed according to the structural data obtained for some hybrid fragments that all hybrid 
fragments from the matrix table are able to reach a deep hydrophobic pocket (also called “affinity 
pocket”) within the ATP binding site (for more details see the chapter 3.3.5. “Insights into inhibitor 
activity and selectivity”). Within a column or a row of the matrix table the appropriate scaffolds and 
hybrid fragments were arranged according to complexity rules that we postulated.  
                                                 
q DOCKING AND SCORING is the process of computationally placing a virtual molecular structure into a binding site 
of a biological macromolecule (docking) and flexibly or rigidly relaxing the respective structures then ranking (scoring) 
the complementarity of fit (Bleicher et al., Nat Rev Dug Discov, 2003). 
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3.2.1. Complexity Rules for Design of Matrix-Template Libraries 
 
By designing the drug-like matrix-template libraries we defined a set of complexity rules used to 
compare the appropriate scaffolds and hybrid fragments that are classified according to their 
complexity. The purpose of such system is to rationalize a designed drug-like matrix library in order 
to get a systematic overview which chemical fragments are responsible for the activity to the related 
targets and which of the most promising regions of the chemical space remain unexplored. 
Two heteroatom containing aromatic groups within a scaffold hopping or a scaffold hybrid 
alignment of the matrix library are compared first by ring largeness of the heterocyclic aromatic 
system. The aromatic one-ring systems have lower complexity in comparison with two- or more-
ring aromatic systems respectively fused aromatic systems; for example the aniline moiety as a one-
ring system has lower complexity than the two-ring containing indole moiety (Figure 9A). Two 
aromatic one-ring systems (Figure 9B) or the aromatic two- or more-ring systems (Figure 9C) are 
compared by decreasing atomic number of the atoms directly attached to them or their substituents; 
the group having the atom of lower atomic number receives lower complexity (for example the 
toluene moiety has lower complexity as the aniline and further the aniline has lower complexity 
than phenol; additionally a pyridine has the lower complexity than pyrimidine, in turn a triazine has 
the higher complexity than pyrimidine (Figure 9B); for two-ring systems an indene moiety without 
a heteroatom has the lower complexity in comparison with an indole moiety containing a nitrogen 
atom, and further an indole moiety has lower complexity in comparison with the benzofuran group; 
the four heteroatom containing oxazolopyrimidine has in comparison with benzofuran and 
furopyrimidine the highest complexity (Figure 9C)). In addition, aromatic substitution with a 
primary amine provides a ligand, which has lower complexity than the ligand that was substituted 
with a secondary amine such as morpholine (see the matrix table, Figure 10). In case of 
regioisomers such as 6- and 2-substituted pyrimidine dimorpholine (matrix table, Figure 10), the 
lower complexity has such group whose aromatic carbon atom on which the hybrid fragment is 
attached has lower complexity according to the rule of decreasing atomic number of attached 
substituents (for example regioisomer 1 from figure 10 has lower complexity than regioisomer 2). 
    
Vladimir Cmiljanovic  Targeting lipid signalling in cancer 
 -69-
 
NH2 HN
indoleaniline
<
(A) ring largeness
NH2
aniline
<
OH
phenol
CH3
toluene
<
(B) decreasing atomic number of attached substituents
N
N
N
R1
triazine
<
N
N
R1
pyrimidine
<
R2 R3 R2 R3N
R1
pyridine
R2 R3
O
benzofuranindene
H
N
indole
< <
O
benzofuran
N
N
O
furopyrimidine
N
N N
O
oxazolopyrimidine
< <
Comparison by:
Purpose of the complexity rules:
systematic overview of chemical fragments
responsible for the inhibitor activity & selectivity
 
Figure 9. Complexity rules for the design of matrix-template libraries. Complexity increases from left to right. (A) Two 
heteroatom containing aromatic groups within a scaffold hopping or a scaffold hybrid alignment of the 
matrix library are compared first by ring largeness of the heterocyclic aromatic system. The aromatic one-
ring systems have higher priority in comparison with two- or more-ring aromatic systems respectively fused 
aromatic systems; for example the aniline moiety as a one-ring system has higher priority than the two-ring 
containing indole moiety. (B-C) Two aromatic one-ring systems or the aromatic two- or more-ring systems 
are compared by decreasing atomic number of the atoms directly attached to them or their substituents; the 
group having the atom of lower atomic number receives higher priority; for example the toluene moiety has 
higher priority as the aniline and further the aniline has higher priority than phenol; additionally a pyridine 
has the higher priority than pyrimidine, in turn a triazine has the lower priority than pyrimidine; for two-ring 
systems an indene moiety without a heteroatom has the higher priority in comparison with an indole moiety 
containing a nitrogen atom and further an indole moiety has higher priority in comparison with the 
benzofuran group; the four heteroatom containing oxazolopyrimidine has the lowest priority and highest 
complexity in comparison with benzofuran and furopyrimidine. 
 
Each scaffold fragment of the matrix table was correlated with each hybrid fragment leading to 
the appropriate compounds whose activity was measured in vitro and in cell. For every matrix 
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compound a pie chart (or a circle graph) is presented, which summarizes the biological activity of 
the compound; blue colour of the pie chart presents the cellular pPKB/PKB remaining activity, 
purple colour presents the cellular pS6 activity (phosphorylated S6 ribosomal protein, another 
marker of Akt/mTOR activation) and the brown colour presents in vitro activity for PI3Kα; for each 
pie it is imperative that the smaller the pie slice is the better is the appropriate activity (Figure 10). 
Additionally the backgrounds in the matrix table of the compounds with very good binding 
affinities are colored yellow, and those with good affinities are blue. Such matrix table gave us a 
great overview by visualising which scaffolds and hybrid fragments should be combined in order to 
refine the activity and the selectivity of relevant hit compounds.  
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3.3. Hit to Lead Optimization 
 
After identification of hitsr (compounds with yellow and blue backgrounds in matrix table, 
Figure 10) from the matrix library a hit-to-leads follow up began by applying different medicinal 
chemistry strategies. By performing hit development using matrix-template strategy, we observed 
that the most compounds were cellular permeable and non-toxic in cellular systems. Last but not 
least, all compounds from the matrix-template library satisfy Lipinski’s rule of fivet [Lipinski, 1997 
#145] in terms of drug-likenessu.  
By selecting the patented scaffolds for the matrix library, we considered ligand complexity and 
chemical tractability (suitability of a compound for chemical modification) as parameters for 
medicinal chemistry optimizations. Higher priority in the matrix library was given for molecules 
that are easier to synthesize and more amenable for structure-activity-relationship (SAR) 
development. The more positions on a scaffold that can be modified using robust chemistry, the 
more diverse are the analogs that can be accessible for the collection of SAR information. From 78 
compounds of the matrix library 28 cell-permeable compounds were identified with good to very 
good in vitro and cellular activity. Figure 11 summarizes cellular and in vitro activity of the matrix-
hit-compounds, which were further optimized by applying different medicinal chemistry strategies.  
Figure 12 summarizes the cellular pPKB/PKB and in vitro PI3Kα activity of all hit compounds and 
their analogues, which were obtained through the medicinal chemistry optimizations of our highly-
motivated research team. 
                                                 
r HIT is „a primary active compound(s) with non-promiscuous binding behaviour, exceeding a certain threshold value in 
a given assay(s). The “active” is followed up with an identity and purity evaluation, an authentic sample is then 
obtained or re-synthesized and activity confirmed in a multi-point activity determination to establish the validity of the 
hit (validated hit)” (Bleicher, K.H., et al., Hit and lead generation: beyond high-throughput screening. Nat Rev Drug 
Discov, 2003. 2(5): p. 369-378). 
s LEAD is “a prototypical chemical structure or series of structures that demonstrate activity and selectivity in a 
pharmacological or biochemically relevant screen. This forms the basis for a focused medicinal chemistry effort for lead 
optimization and development with the goal of identifying a clinical candidate. A distinct lead series has a unique core 
structure and the ability to be patented separately”. 
t LIPINSKI’S RULE OF FIVE is a rule to evaluate druglikeness, or determine if a chemical compound with a certain 
biological activity has properties that would make it a orally active drug in humans. The rule was formulated by 
Christopher A. Lipinski in 1997, based on observation that most medication drugs are relatively small and lipophilic 
molecules. The rule says, that, in general, an orally active drug has to fulfil following criteria: (a) not more than 5 
hydrogen bond donors (nitrogen or oxygen atoms with one or more hydrogen atoms); (b) not more than 10 hydrogen 
bond acceptors (nitrogen or oxygen atoms); (c) a molecular weight under 500 daltons; (d) an octanol-water partition 
coefficient logP is less than 5. 
u DRUG-LIKENESS is a scoring metric (computational) for the similarity of a given structure to a representative 
reference set of marketed drugs (Bleicher, K.H., et al., Hit and lead generation: beyond high-throughput screening. Nat 
Rev Drug Discov, 2003. 2(5): p. 369-378). 
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Figure 11. Biological activity of 28 cell-permeable compounds with good to very good biological activities that 
were identified from the preselected library of 78 compounds. All compounds were rapidly characterized by 
high-throughput screening assays such as in-cell Western method and in vitro method for profiling against 
PI3Kα. The identified hits were further optimized by applying different medicinal chemistry strategies.  
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Figure 12. Summary of best inhibitors at 200 nM in vitro (above) and at 1 µM by in-cell Western method 
(below), where inhibitor efficacy was measured by pS6 Ser 235/236 detection. The higher the pPKB/PKB values 
are the less strong is the inhibition of signalling. 
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3.3.1. Medicinal Chemistry Application of Fluorine 
 
Carbon-bound fluorine atoms are unique in organic chemistry. Fluorine is a small atom with a 
very high electronegativity [22]. With a van der Waals radius of 1.47 Å [23], covalently bound 
fluorine occupies a smaller volume than a methyl, amino, or hydroxyl group, but is larger than a 
hydrogen atom (van der Waals radius of 1.2 Å). While synthetic fluoro-organic chemistry has 
matured over recent decades, the specific use of fluorine in small-molecule drug-discovery research 
is more recent. Fluorinated compounds are nowadays synthesized in pharmaceutical research on a 
routine basis [24]. According to the World Drug Index (WDI), there are 128 fluorinated compounds 
with US trade names [25].  
Current strategies for the introduction of fluorine atoms center on the following topics [25]: 
 
3.3.1.1. Improving Metabolic Stability With Fluorine 
 
Metabolic stability is one of the key factors in determining the bioavailability of a compound. 
Rapid oxidative metabolism by the liver enzymes, in particular the P450 cytochromesv, is often 
found to limit bioavailability. A frequently employed strategy to circumvent this problem is to 
block the reactive site of the relative compound by the introduction of a fluorine atom. There are 
many examples illustrating that the replacement of an oxidizable C-H group by a C-F group 
increases metabolic stability of the molecule [25].  
 
3.3.1.2. The Effect of Fluorine on Physicochemical Properties 
 
3.3.1.2.1. The Effect of Fluorine on the pKa 
 
As the most electronegative atom, fluorine has a very strong effect on the acidity or basicity of 
nearby functional groups. Depending on the position of the fluorine substituent relative to the acidic 
or basic group in the molecule, a pKa shift of several log units can be observed. For example, the 
pKa’s of acetic acid and its α-fluorinated analogues are 4.76 (CH3COOH), 2.59 (CH2FCOOH), 1.24 
(CHF2COOH), and 0.23 (CF3COOH) [25]. Highly basic groups can have a limiting effect on the 
bioavailability. A fluorine atom introduced close to a basic group reduces its basicity; this results in 
                                                 
v CYTOCHROME P450 is a family of iron-haem-containing enzymes involved in oxidative metabolism of a broad 
variety of xenobiotics and drug compounds. 
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better membrane permeation of a compound and thus improved bioavailability. For example, the 
basicities of ethylamine and its β-fluorinated analogues, measured by the pKa’s of the protonated 
amines, decrease in an approximately linear fashion upon introduction of fluorine, the pKa’s being 
10.7 (CH3CH2NH2), 8.97 (CH2FCH2NH2), 7.52 (CHF2CH2NH2), and 5.7 (CF3CH2NH2) [25]. Quite 
often, a change in the pKa has a strong effect on both the pharmacokinetic properties of the 
molecule and its binding affinity. For example, a strongly basic group may be required for binding 
within a certain lead series, but at the same time this basic group may also be found to result in 
compounds with low bioavailability due to the limited ability of a strong basic group to pass 
through membranes.  
 
3.3.1.2.2. The Effect of Fluorine on Molecular Lipophilicity 
 
Lipophilicity is a key molecular parameter in medicinal chemistry. Typically, groups of 
substantial lipophilicity on the ligand are required to obtain a good binding affinity to the target 
protein [25]. However, a high lipophilicity typically results in a reduced solubility and a number of 
other undesirable properties for a compound. Therefore, the right balance between a required 
lipophilicity and a certain minimal overall polarity of the molecule is one of the recurring 
challenges for medicinal chemists. 
The substitution of a hydrogen atom by fluorine increases lipophilicity slightly, by roughly 0.25 
logDw units [25]. Interestingly, there are quite a number of cases for which an H to F substitution 
decreases lipophilicity (Figure 12a) [25]. This is the case, when an oxygen atom is close to the 
fluorine by the relevant compound. One possible explanation, is that fluorine in close vicinity to an 
oxygen atom increases the overall polarity of the molecule, leading to a more pronounced gain in 
solvation energy in the polar medium relative to the nonpolar solvent [25]. However, it is also 
possible that the fluorine polarizes the neighboring oxygen atoms and this leads to stronger 
hydrogen bonds between the oxygen and neighboring water molecules.  
 
F
OR
F O F
O
 
Figure12a. Examples where an H to F substitution decreases lipophilicity. 
 
 
                                                 
w LogD is the logarithmic coefficient of the distribution of the compound between octanol and water at a given pH 
(typically 7.4). 
    
Vladimir Cmiljanovic  Targeting lipid signalling in cancer 
 -77-
3.3.1.3. The Effect of a Fluorine Substitutent on Molecular Conformation 
 
A fluorine substitutent can lead to a change in the preferred molecular conformation. Again, this 
effect can be explained by the size and electronegativity of fluorine. Based on a van der Waals 
radius of 1.47 Å for fluorine, the volume of a trifluoromethyl group is roughly twice that of a 
methyl group. As a result, the effect of fluorine substitution on molecular conformation is quite 
subtle and sometimes difficult to predict [25]. 
 
3.3.1.4. The Role of Fluorine in Protein-Ligand Interactions 
 
Fluorine can have significant effects on the binding affinity in protein-ligand complexes. This 
effect can be direct by interaction of the fluorine with the protein, or it can be indirect by 
modulation of the polarity of other groups of the ligand that interact with the protein [25]. For 
example, most of the NK1 antagonists currently in clinical development contain a 3,5-
di(trifluoromethyl)phenyl group to increase binding affinity [26]. Additionally, fluorine can have a 
role in polar interactions. Lessons from a set of fluorine-substituted thrombin inhibitors demonstrate 
that C-F···C=O interactions can play an important role in protein-ligand interactions and can lead to 
significantly increased binding affinities [25]. 
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Figure 12b. Insertion of a fluorine to the presented thrombin inhibitor increases the inhibitor activity according to the 
C-F···C=O interaction of the thrombin inhibitor and the asparagine moiety of the target protein.  
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3.3.1.5. Applying Fluorine Strategy on PI3K Inhibitors 
 
We could successfully apply fluorine strategy on our own research. Fluorine was systematically 
introduced at various positions of the inhibitor skeleton to explore the binding affinity and specific 
interactions of the halogen with active-site amino acid residues of the enzyme. In several examples 
insertion of fluorine dramatically enhanced the biological activity of the relevant hit-inhibitor. For 
example, compound 97 (NCA163) (Figure 13) from the matrix library was identified as a hit with 
good cellular and in vitro properties. Insertion of trifluoromethyl group on the 4-position of the 
pyridine ring of 97 (NCA163) led to the analog 98 (NCB5), which showed excellent activity in 
melanoma cancer cell lines (Figure 13). We determined the X-ray crystal structure of NCB5 in 
complex with PI3K (Figure 13). 4-(trifluoromethyl)pyridin-2-amine group of 98 (NCB5) is going 
into deep hydrophobic pocket of the enzyme, where a fluorine atom of the trifluoromethyl group is 
within hydrogen-bonding distance of the N-H group of the catalytic Lys-883. Therefore, this 
interaction mode certainly constitutes a favourable dipolar interaction. Whether one wants to call 
this a hydrogen bond remains a matter of personal taste. Interestingly, insertion of CF3-group led to 
nine times more potency in vitro against PI3Kα (Figue 13). Molecular modelling experiments with 
the PI3Kα crystal structure demonstrated that in comparison with PI3K isoform the 4-
(trifluoromethyl)pyridin-2-amine group of 98 (NCB5) was better fited within the ATP-binding 
pocket and therefore more hydrophobic contacts with the protein were obtained. IC50 measurements 
of 98 (NCB5) for class I PI3Ks and for mTOR demonstrate that this compound is selective pan-
PI3K inhibitor with low-nanomolar activity (IC50: PI3Kα (20 nM), PI3Kβ (15 nM), PI3Kδ (38 nM), 
mTOR (>1000 nM)). This example from our own research is an additional example, which 
demonstrates that fluorine can have significant effects on binding affinity in protein ligand 
complexes. 
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Figure 13. Fluorine effect on PI3K inhibitor 97 (NCA163). Presented is cellular activity (pPKB/PKB and pS6 bar 
charts) at 1 µM and in vitro activity against PI3Kα at 200 nM; the lower the bar chart the better is the activity of the 
relevant compound. Insertion of trifluoromethyl group led to considerable increased cellular activity and nine times 
more potency in vitro against PI3Kα. According to the X-ray crystal structure a fluorine atom of the trifluoromethyl 
group is within hydrogen-bonding distance of the N-H group of the catalytic Lys-883. Second morpholine moiety 
makes an additional H-bridge formation with Lys-890. 
 
Another very interesting example from our own research is the fluorine effect on compound 114 
(NCB53, matrix coordinate: M4) (Figure 13b). Compound 114 (NCB53) was identified as a hit 
from the matrix-template library. The literature known analog of this compound is the pan-PI3K 
selective inhibitor 115 (ZSTK474) from the Japanese pharmaceutical company Zenyaku Kogyo, 
which is the first orally available PI3K inhibitor. ZSTK474 is currently in clinical phase I. 
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We investigated the effect of replacing hydrogen atoms from the methyl group of compound 114 
(NCB53) by a fluorine atom on the molecular conformation of the compound as well as protein-
ligand interactions. Insertion of trifluoromethyl group to the benzimidazole moiety led to the 
compound 116 (NCA111), which was poorly active in cellular assays. Interestingly, insertion of 
difluoromethyl group to the benzimidazole provided the known compound ZSTK474, which has 
been shown to be the most potent benzimidazole-containing triazine derivative. With the aim to 
explore the effect of difluoromethyl group on the ligand activity, we determined the X-ray structure 
of ZSTK474 bound to PI3K (Figure 13c). According to the X-ray structure fluorine of 
difluoromethyl group plays an important role as an acceptor for H-bridge formation. A similar H-
bridge formation was observed for fluorine from the trifluoromethyl group of 98 (NCB5). Further 
efforts in analytical chemistry (NMR) explained that the reason for specific binding mode of 
ZSTK474 is an intramolecular H-bridge formation between hydrogen atom of the difluoromethyl 
group and nitrogen of the triazine scaffold (Figure 13c). The intramolecular H-bridge could not be 
obtained by NMR due to the symmetry of the ligand ZSTK474. To obtain the intramolecular H-
bridge formation we broke the symmetry of the compound through the exchange of one morpholin 
ring with the dimethyl morpholin ring. By using Exchange NMR-Spectroscopy (EXSY) we were 
able to identify two possible conformers of the asymmetric ZSTK474 analog, compound NCB136, 
and to obtain their activation enthalpies G‡[kJmol–1] (Figure 13d). These results suggest that 
ZSTK474 is able, with help of the difluoromethyl group, to preorganize a specific symmetry before 
binding to the active-side of the protein. Intramolecular hydrogen bond formation of ZSTK474 can 
be explained with basicity of nitrogen atoms of triazine ring by analysing acid-base properties of 
well-characterized pyridine derivatives such as DMAP (Figure 13e). With such chemistry 
informations we were able to elucidate the selectivity mechanism of ZSTK474. One of two possible 
conformers of ZSTK474 within the protein binding pocket has been observed through the X-ray 
crystal structure where two H-bridge formations characterize the PI3K-ligand complex (Figure 
13c). By docking the same ligand to the modeled mTOR structure we obtained the second possible 
conformer as the conformer with the highest binding energy to mTOR (Figure 13c). We proposed 
that due to the steric reasons and different ATP-binding pockets of class I PI3Ks and mTOR the 
conformer 1 is prefered by PI3Ks and conformer 2 by mTOR. Additionally by mTOR the H-bridge 
formation with the catalytic lysine residue is lost leading to the poor inhibitor activity to mTOR and 
therefore high class I PI3K selectivity (Figure 13c).  
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Figure 13b. Fluorine effect on ZSTK474. Presented is cellular inhibitor activity measured with pPKB, PKB and pS6 
biomarkers in A2058 melanoma cells at 1 µM and in vitro inhibitor activity against PI3Kα at 200 nM; the lower the 
bar chart the better is the activity of the relevant compound. Trifluoromethyl group containing inhibitor 101 (NCA111) 
has lower activity as difluoromethyl group containing inhibitor (ZSTK474). 
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Figure 13c. (A) According to the X-ray crystal structure fluorine of the difluoromethyl group plays an important role as 
an acceptor for H-bridge formation. Specific interaction with Lys-833 within the ATP binding pocket leads to an 
appropriate binding mode of ZSTK474. Further efforts in analytical chemistry explained that the reason for such 
specific binding mode of ZSTK474 is an intramolecular H-bridge formation between hydrogen atom of the 
difluoromethyl group and the nitrogen atom of the triazine scaffold. (B) By docking the same ligand to the modeled 
mTOR structure the second possible conformer, as the conformer with the highest binding energy to mTOR and formed 
through the C-N bond rotation of the benzimidazole, has been observed. (C and D) We proposed that due to the steric 
reasons and different ATP-binding pockets of class I PI3Ks and mTOR the conformer 1 is prefered by PI3Ks and 
conformer 2 by mTOR. Additionally by mTOR the H-bridge formation with the catalytic lysine residue is lost leading 
to the poor inhibitor activity to mTOR and therefore high class I PI3K selectivity. 
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LT/HT experiments on NCB-136: 
 
assignment δ[ppm] δ[Hz] Tcoalesc.[K] G‡[kJmol–1] k(Tcoalesc.)[s–1] 
H-3 Morph. 3.9 37.7 290 60.1 83.7 
H-3e Me2M. 4.5 58.3 336 68.9 129 
H-3a Me2M. 2.7 48.4 330 68.1 107  
 
Figure 13d. With the help of Exchange NMR spectroscopy (EXSY-NMR) two possible conformers of the compound NCB136 
have been identified. The obtained signals from EXSY spektren were used to calculate the activation enhalpie G‡[kJmol–1]. 
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Figure 13e. The nitrogen atom has high pKa as pyridine through the influence of dimethylamino group, which has 
electron donor properties. DMAP can be compared with the morpholino group containing triazine derivative 
concluding that the nitrogen atoms on triazine scaffold are more basic and favour the intramolecular H-bridge 
formation with the difluoromethyl group. 
 
3.3.2. Medicinal Chemistry Application of Sulfone Functional Group 
 
The sulfone group is an important module in medicinal chemistry. It share its high electron 
withdrawing effects with groups like CF3 or CN [27]. However, unlike the CF3 group whose 
introduction into a given scaffold typically increases lipophilicity [25], or the nitrile group, which 
results in lipophilicity reduction only when introduced into saturated structural domains, a sulfone 
unit more or less lowers the lipophilicity of a compound independently of its structural location 
[27]. All three groups affect the basicity of nearby basic functional groups. The marked electron 
withdrawing and basicity-lowering effect of a sulfone group in a saturated system is best illustrated 
by the very weak basicity of thiomorpholine 1,1-dioxide (1a, Figure 14), the sulfone analogue of 
morpholine (1b, Figure 14). The reduction of the amine basicity, pKa, by approximately six log 
units relative to piperidine (1c) can be interpreted in terms of an amine basicity-lowering effect of 
almost three log units through each of the two -brances [27] in the six-membered ring, exerted by 
the SO2 group in the β-position to the amine function.  
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1c  
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1d  
pKa 5.4 8.5 11.1 9.0 
pKa -5.8 -2.6 0 -2.1 
½ pKa -2.9 -1.3 0 -1.1 
Figure 14. Experimental pKa values of thiomorpholine 1,1-dioxide (1a), morpholine (1b), piperidine (1c), and 
thiomorpholine (1d) [27]. 
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Sulfone strategy could be successfully applied for the optimization of ZSTK474, where a 
morpholine ring was replaced with thiomorpholine 1,1-dioxide (1a) providing compounds 140 and 
and 140b (Figure 15), and sulfonyl piperazine derivatives (compounds 141 and 142, Figure 15). 
Insertion of 1a to ZSTK474 and to non-fluorinated ZSTK474 analog led to compounds 140 and 
140b (Figure 15) and reduction in biological activity. Interestingly, insertion of 1-
(methylsulfonyl)piperazine led to 141, which showed more potent activity in vitro and in cancer cell 
lines as ZSTK474. According to our molecular modelling experiments it was obvious that the 
oxygen atom of sulfonyl group has the potential to form an additional hydrogen bond with the target 
protein making this compound more potent. Advantageously, compound 141 has due to the polarity 
of the sulfonyl group better water solubility as ZSTK474.  
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Figure 15. Optimization of ZSTK474 by applying sulfone strategie. The smaller the bar charts are the more potent are 
the relevant compounds.  
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3.3.3. Spirocyclic Oxetane Derivatives as Novel Promising PI3K Inhibitors 
 
Despite very important function of morpholine in drug discovery making compounds more water 
soluble and less lipophilic, almost all of morpholino containing PI3K inhibitors have solubility 
problems under cellular conditions and therefore in several cases poor oral bioavailability (e.g. PI-
103) (all literature known morpholino containing PI3K inhibitors were synthesized in the research 
group of Prof. B. Giese and their activity was tested in different cellular assays by colleagues from 
the research group of Prof. M. Wymann). With this background information we decided to expand 
the chemical space around morpholine. Novel molecules were designed where the morpholine 
moiety was exchanged with spirocyclic oxetane 263 (Figure 16), which is known from very recent 
studies of ETH Zürich and Roche Basel researchers (Prof. Erick M. Carreira, Prof. Klaus Müller 
and colleagues) to be able to successfully replace a morpholino unit [28]. By comparing spirocyclic 
oxetane 263 and morpholine (262) (Figure 16) one can reveal several interesting features. 
Spirooxetane 263 is more slender than morpholine (Figure 16), and the position of the oxygen atom 
of spirooxetane is in comparison with the oxygen atom of morpholine extended with 1.3 Å in the 
molecular symmetry plane. The lone pairs of electrons on the oxygen atom in spirooxetane have the 
spatial orientation, in morpholine (260) they are orthogonal (Figure 16). Furthermore, in 
spirooxetane the oxygen atom is colocated and in morpholine not according to different chair 
conformations of morpholine observed by X-ray structures of inhibitor•PI3K complexes.  
The spirocyclic analog of morpholine, 2-oxa-6-azaspiro[3.3]heptane (263), is with solubility of 
24’000 µg/ml three times more soluble than morpholine (262) (Table 2). Such solubility feature is 
explained by lower LogP (intrinsic lipophilicity) and LogD (lipophilicity or logarithmic n-
octanol/water distribution coefficient at pH = 7.4) than that of morpholine (Table 2). Additionally, 
the lipophilic parts of spirooxetane 263 (also called as “homospiromorpholine”) are concentrated 
around the central quaternary carbon while both its oxygen and nitrogen are exposed to the solvent. 
Moreover, according to human and in mouse liver microsomes, metabolic liability of spirooxetane 
is reduced [28]. All these observations together with its ease of preparation make spirooxetane 263 
a very promising candidate of replacing morpholine as a solubilising group.  
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Figure 16. (A) Superposition of three structures: the X-ray crystal structures of the N-benzhydryl derivative of 
spirooxetane 263 and N-methylmorpholine (green), and a model of N-methyl-4-piperidone (ochre) (blue; the 
benzhydryl group is omitted, the crystallographic data can be obtained from The Cambridge Crystallographic Data 
Center via www.ccdc.cam.ac.uk/data_request/cif; the crystallographic data code for N-benzhydryl derivative of 
spirooxetane 263 is CCDC675323; adapted from Wuitschik et al. [28]). (B) Calculated van der Waals surfaces of 
spirooxetane and morpholine with the software Accelrys Discovery Studio 2.5. Position of the oxygen atom of 
spirooxetane is in comparison with the oxygen atom of morpholine extended with 1.3 Å in the molecular symmetry 
plane. 
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Table 2. Physicochemical and biochemical properties (adapted from [28]).a 
Structure logDb logPc Sol.d CIinte pKaf 
N
O
R  
0.5 1.2 24000 3/7 8.0 
N
O
R  
1.5 1.6 8000 9/8 7.0 
aR = piperonyl. bLogarithmic n-octanol/water distribution coefficient at pH 7.4. cIntrinsic lipophilicity of the neutral 
base according to the equation logP = logD+log10(1+10(pKa-pH)). dIntrinsic solubility of the neutral base. The values were 
obtained from the experimental thermodynamic solubility [µgmL-1] in phosphate butter (50 mM) at pH 9.9 and 22.5±1 
°C, and corrected for the pKa value. eIntrinsic clearance rates [min-1mg-1µL] measured in human and mouse liver 
microsomes.  fAmine basicity in water measured spectrophotometrically at 24 °C. 
 
Designed spirooxetane derivatives (Table 3) were automatically docked in the crystal structure 
of PI3Kα (PDB code: 2RDO) and their binding mode orientations and binding energies were 
studied pre and after minimization and quick dynamics. The H-bridge formation of morpholino 
oxygen and the backbone amide of Val-851 was observed by all docked spirooxetane containing 
compounds from Table 3. The best energy scores were observed for compound 257 (GSA44), 
which was designed by substituting one morpholine ring with the spirooxetane 263 of inhibitor 
ZSTK474, which contains two morpholine units (Table 3 and Figure 17) both included in target 
binding according to our X-ray structure in complex with PI3K. All of the docked spirooxetane 
containing compounds were successfully synthesized and tested in vitro for PI3Kα and in cellular 
cancer cell lines. The best experimental values were obtained for 257 (GSA44), which was in 
agreement with in silico results. Compound 254 (GSA61), which contains two spirooxetane units 
instead of two morpholines, was not active in cells and had poor activity in vitro. This compound 
was poorly soluble in all organic solvents and also in DMSO, which was used to dilute the 
substance for cellular assays and therefore we assumed that 254 (GSA61) could be also not cell 
permeable. To exclude the unfavourable solubility and the cell permeability factors of 254 (GSA61) 
we synthesized compounds 250 (GSA73) and 252 (GSA74) where one morpholine of the known 
inhibitor ZSTK474 (115) was exchanged with the spirooxetane moiety and the second morpholine 
was exchanged with certain piperazine derivatives known from previous experiments to be 
advantageous to increase the solubility and cell permeability of the whole ligand when attached 
directly to the triazine scaffold. Compounds 250 (GSA73) and 252 (GSA74) were also inactive in 
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cells and showed poor in vitro activity against PI3Kα concluding that only one morpholine ring of 
ZSTK474 (115) can be successfully replaced by spirooxetane 263. According to the molecular 
modelling results, in vitro and in cell data observed by triazine derivative 257 (GSA44), the 
presence of one morpholine ring is essential for target recognition and key-hydrogen bonding with 
the hinge valine (Val-851 by PI3Kα, Val-854 by PI3Kβ, Val-882 by PI3K and Val-828 by PI3Kδ) 
(Figure 18). Moreover, this observation was additionally confirmed by using the compound 264 
(GSA65_2), where the morpholine ring of inhibitor PI-103, needed for the ligand activity by 
interacting with the hinge valine, was replaced with the spirooxetane moiety. Such morpholine-
spirooxetane replacement induced a lost in biological activity of 264 (GSA65_2) (for cellular and in 
vitro data see below). Last but not least, our crystal structure of ZSTK474 in complex with PI3K 
isoform and its direct comparison with the crystal structure of PI3K in complex with in silico 
docked and minimized 255 (GSA44) provides a visual overview, that morpholine ring, which is 
going out of the binding pocket to solvent environment, is able to be successfully replaced with the 
spirooxetane 263 (Figure 19).  
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Figure 17. Design of spirocyclic oxetane containing phosphoinositide 3-kinase inhibitors. (A) The morpholine ring of 
pyridinylfuropyrimidine (PI-103), which is involved in the target binding, was replaced with spirooxetane (colored in 
blue). (B) The morpholino moieties of ZSTK474 were differently replaced with spirooxetanes leading to the active and 
inactive asymmetric compounds. 
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Table 3. Molecular modelling data obtained for spirooxetane containing compounds 
Structure ID PI3Kα Scorea 
kcal 
bE beforeb 
kcal/mol 
bE 
afterc 
Total PI3K Scorea 
mTOR 
Scorea 
N
N
N
N
O
NN
O
N
F F
 
257 
(GSA44) 59.34 39.87 114.844 -23600 69.03 71.53 
N
N
N
N
NN
O
N
O
F F
 
254 
(GSA61_s3) 55.26 -69.92 112.425 -23185 56.48 70.11 
N N
NN N
N
O
N
N
S
O
O
F F
 
250 
(GSA73_s2) 57.58 82.8772 127.719 -23047 63.72 63.68 
N N
NN N
N
O
N
N
F F
 
252 
(GSA74) 58.19 -137.991 70.123 -23154 67.75 66.74 
N
N
O
N OH
N
O
 
264 
(GSA65_2) 51.26 -657.304 108.056 -22824 58.46 67.27 
aDocking score is the energy giving by the docking program, the more positive the better. There is no correlation 
between score and the binding energy. bbE before is the binding energy after docking prior any minimization and quick 
dynamics, the higher the better. cbE after is the binding energy after minimization and quick dynamics, the higher the 
better. 
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Figure 18. Targeting phosphoinositide 3-kinase (PI3K) with spirooxetane containing ATP-competitive inhibitors. (A-E) Ribbon diagrams 
of PI3Kα crystal structure (PDB code: 2RDO) in complex with in silico docked inhibitors and zoomed into the ATP-binding site. The 
binding energies and the binding mode orientations of the depicted inhibitors were compared pre and after the minimization and quick 
dynamics of the ligand·PI3Kα complexes. Val-851, which is responsible by PI3Kα for the interaction with the morpholino oxygen of 
morpholino ring containing PI3K inhibitors, and the ligands are represented in stick form, colored according to the element (C atoms in 
grey, N atoms in blue, O atoms in red). (A) Ligand 257 (GSA44) showed in comparison to all other docked ligands the best binding 
energies and it was obvious that the morpholino ring of 257 (GSA44) is required for high binding energy of the ligand by making an H-
bridge formation with Val-851, where the spirocyclic oxetane moiety is located in the hydrophobic pocket II going outside of the binding 
pocket in a solvent environment direction. This observation was successfully confirmed with experimental in vitro and in cell results 
from the SAR studies (for data see below). (B-E) In silico the spirocyclic oxetane ring was able to successfully recognize Val-851 with 
satisfied ligand binding energies; in vitro and in cell the compounds were inactive leading to the observation that spirocyclic oxetane can 
not replace the morpholine responsible for binding with the hinge valine of PI3K.  
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Figure 19. Targeting phosphoinositide 3-kinase (PI3K) with spirooxetane containing ATP-competitive inhibitors. (A-B) 
Ribbon diagram of PI3K crystal structures zoomed into the ATP-binding site. Amino acids residues and the ligands are 
represented in stick form, colored according to the element (C atoms in grey, N atoms in blue, O atoms in red). Numbers 
denote highlighted, prominent side chains mediating PI3K/ligand interactions; the hydrogen bonds with Val-882 
correspond to the contact lists. (A) Ribbon diagram of PI3K crystal structure in complex with 115 (ZSTK474). One 
morpholine ring of the symmetric inhibitor makes the H-bridge formation with Val-882, an interaction conserved in all 
PI3K inhibitors; the second morpholine ring is located in so-called hydrophobic region II within the ATP-binding pocket, 
where it makes hydrophobic interactions with Lys-890 and is going out of the binding pocket to the solvent environment. 
(B) Ribbon diagram of PI3K crystal structure with in silico docked asymmetric inhibitor 257 (GSA44). The binding 
energies of three most relevant binding mode orientations (interaction of Val-882 with whether the morpholine or 
benzimidazole or spirooxetane unit) were compared pre and after the minimization and quick dynamics of the ligand·PI3K 
complex. The presented orientation of 257 (GSA44) showed the best binding energies and is comparable with the most 
stable binding orientation observed by PI3Kα isoform. The spirocyclic oxetane moiety is located in the hydrophobic region 
II going outside of the binding pocket in a solvent environment direction. 
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Table 4a. Cellular and in vitro data obtained for spirooxetane containing compounds 
Structure ID 
In vitro 
PI3Kα 
200nM 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM 
pS6 
1 µM 
pS6 
10 µM 
N
N
N
N
O
NN
O
N
F F
 
257 
(GSA44) 36 ++++ ++++ +(+) ++++ 
N
N
N
N
O
NN
O
N
CH3
 
256 
(GSA42) 90 (+) ++++ - - 
N
N
N
N
NN
O
N
O
F F
 
254 
(GSA61) 100 - - - - 
N
N
N
N
NN
O
N
CH3
O
 
253 
(GSA53) 107 - - - - 
N N
NN N
N
O
N
N
S
O
O
F F
 
250 
(GSA73) 103 - - - - 
N N
NN N
N
O
N
N
F F
 
252 
(GSA74) 104 - + - - 
N
N
N
O
NN
O
N
F F
 
261 
(GSA81) ND ND ND ND ND 
N
N
N
NN
O
N
F F
O
 
259 
(GSA80_2) ND ND ND ND ND 
N
N
O
N OH
N
O
 
264 
(GSA65_2) 102 - - - - 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is 
the stronger is the inhibition. ND (not defined) 
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3.3.4. Summary of the Most Active Inhibitors 
 
The follow figures summarize the most active inhibitors obtained after the hit-to-lead 
optimization of the compounds identified from the matrix library.  
Figure 20 shows that ZSTK474 was one of the most potent benzimidazole-containing triazine 
derivatives followed by sulfonyl containing ZSTK474-derivative (compound NCB60), N-methyl 
piperazine ZSTK474 derivative (compound NCB36) and oxetane containing ZSTK474-derivative 
(GSA44). GSA44 has weaker inhibitor activity in comparison with ZSTK474, but it has better 
solubility. Further efforts are on-going to proof the oral bioavailability of GSA44. 
 
Figure 20. The most potent ZSTK474 analogues. Connected are pyrimidine and triazine scaffolds with the same 
substituents. The lower the bar charts the better are appropriate cellular and in vitro activities. 
 
Figure 21 presents best triazine derivatives with an aminopyridine or aminopyrimidine moiety. By 
analyzing this figure one can obtain that in almost all cases a triazine derivative is more active in 
cell as the corresponding pyrimidine analog.  
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Figure 21. The most potent NCB15 analogues. Connected are pyrimidine and triazine scaffolds with the same 
substituents. Through the red line connection one can obtain the difference in the bioactivity by insertion of –CH3 or –
CF3 groups. The lower the bar charts the better are appropriate cellular and in vitro activities. 
 
Compound MJA40 (Figure 22) has been found to be a hit, which could not be optimized through 
the previous described strategies. Still, MJA40 is one of the most potent compounds identified from 
the matrix library. Very interesting is the selectivity of this compound; it shows high cellular 
activity and high isoform selectivity against PI3Kdelta. This compound did not inhibit PI3Kα, 
PI3Kβ and PI3K. Further structural X-ray analysis in complex with PI3Kdelta is on-going, with 
the aim to explore the isoform selectivity of this compound.  
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Figure 22. The most potent MJA40 analogues. Connected are pyrimidine and triazine scaffolds with the same 
substituents. Compounds VVA123 and VVA115 have been found to be mTOR active according to their cellular 
pS6 detection. The lower the bar charts the better are appropriate cellular and in vitro activities. 
 
Several benzofuro- and thienopyrimidine derivatives were obtained to have attractive bioactivities 
(Figure 23 and Figure 24). The cellular and in vitro results suggest that the matrix strategy was 
successfully applied to gain novel pyridinylfuropyrimidine derivatives with non-dual character for 
further biological validation of PI3Ks. Further in vitro characterizations for mTOR are on-going and 
the novel results will complete the selectivity know-how.  
Best matrix compounds with different selectivites have shown promising anti-proliferative effect 
(Figure 26). 
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Figure 23. The most potent PI-103 analogues. The lower the bar charts the better are appropriate cellular and in 
vitro activities. 
 
Figure 24. The most potent 15e (VCB187) analogues. The lower the bar charts the better are appropriate cellular 
and in vitro activities. 
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Figure 25. Concentration dependent inhibition of PKB phosphorylation. A2058 cells were exposed for 3 hours to 
increasing concentrations of NVP-BEZ235 and NCA235. Total cell lysates were subjected to immuno-blotting 
for total and phosphorylated PKB and phosphorylated p70S6K. Emerging signals were quantified using 
fluorescent secondary antibodies, or enhanced chemiluminescence and ratios of phosphosphorylated over non-
phosphorylated kinase for PKB and the quantified values for p70S6K are displayed. (n>2, mean ± SEM). 
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Figure 26. Anti-proliferative effect of PI3K inhibitors. Melanoma cells were exposed to the indicated inhibitors 
at 1 µM for one, two and three days, before cell numbers were determined with Alamar Blue. Cell numbers are 
depicted in relation to non-treated controls (ratio of treated over non-treated cultures). Data are means of 
triplicates  SEM. 
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3.3.5. Structural Insights into Inhibitor Activity and Selectivity 
 
3.3.5.1. The Active Site of Class I PI3Ks  
 
All of the PI3Ks have a catalytic domain that shows homology with protein kinases. Like protein 
kinases, the catalytic domain of PI3Ks exhibits a bilobal organization with the ATP-binding pocket 
in a cleft between the N- and C-lobes, and PI3Ks share the same conserved catalytic residues in the 
phosphate-binding subsite of protein kinases [14]. Studies of protein kinases in complexes with 
small-molecule ATP-competitive inhibitors have suggested that conformational changes are often a 
part of the catalytic cycle of these enzymes. Most protein kinase inhbitors that have been developed 
target the active conformation of the enzymes so that the inhibitor-bound conformation is very 
similar to the ATP-bound conformation. These have been referred to as the type I inhibitors [29]. A 
pharmacophore model often used to describe binding by the type I protein kinase inhibitors divides 
the ATP-binding site into the hinge region, the hydrophobic pocket regions I and II, the adenine 
region, the ribose region and the phosphate region (Figure 27). 
 
 
Figure 27. Schematic representation of a canonical PI3K/protein kinase ATP-binding pocket (adapted from [30]).  
 
All PI3K-inhibitor complexes that have been reported are type I inhibitors, occupying the 
adenine region and making characteristic hydrogen bonds to the hinge of region of the PI3K [30]. A 
region that has been referred to as hydrophobic region I forms a deeper pocket behind the binding 
site for the ribose moiety of the ATP. In protein kinases, the “gatekeeper” residue, which forms part 
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of the wall of hydrophobic region I, partially restricts access to this region. Kinases with a large 
residue at the gatekeeper position cannot accommodate inhibitors with large substituents in 
hydrophobic region I, whereas kinases with a less bulky gatekeeper can. Among the most common 
resistance mutations of protein kinases is the mutation of a small gatekeeper residue into a larger 
more restrictive residue. The residue in PI3Ks analogues to the gatekeeper residue of the protein 
kinases is an isoleucine residue (Ile-871 in PI3K, data obtained through the collaboration with 
Prof. Roger Williams, University of Cambridge), and this residue forms part of the wall of the very 
small PI3K hydrophobic region I. Many PI3K inhibitors occupy this region. This region has also 
been referred to as the “affinity pocket” in the PI3K-inhibitor complexes [1].  
 
3.3.5.2. Crystal Structures of PI3K/mTOR Inhibitors Developed by Matrix-Template 
Strategy 
 
Here we report details of x-ray crystal structures, structural docking and modelling studies that 
we have conducted for small molecule inhibitors selected from the matrix library. All of these 
molecules are ATP-competitive antagonists (Figures 28, 29 and 30) that exhibit either: 
a) broad class I activity, or  
b) broad class I activity and mTOR, or 
c) class I subtype selectivity and mTOR. 
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Figure 28. Targeting phosphoinositide 3-kinase (PI3K) with small molecule ATP-competitive inhibitors. (A-F) A 
ribbon diagram is presented in green, and the inhibitors, located at the ATP binding site, in the cleft between the N- and 
the C-terminal lobe of the catalytic subunit, are colored by elements. 
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Figure 29. Targeting phosphoinositide 3-kinase (PI3K) with small molecule ATP-competitive inhibitors. (A-F) A 
surface diagram is presented, where the blue points characterize the N-atoms, red points O-atoms, yellow points S-
atoms and grey points C-atoms of the enzyme; the relevant inhibitors, coloured in green, are presented as spheres with 
the aim to represent their filled space within the ATP-binding pocket. 
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We have determined the crystal structures of PI3K in complex with inhibitors 34 (ASA76), 115 
(ZSTK474), 139 (NCB36), 102 (NCB15), 98 (NCB5) and 208 (MJA40) (Figure 30). All of the 
compounds made the key hydrogen bond through the interaction of morpholine oxygen with the 
backbone amide of the hinge Val-882. The crystal structures confirmed that the matrix-hybrid-
fragments are crucial for their high potency, because they are able to occupy the “affinity pocket” 
through the formation of several hydrogen bonds. The contact list with exact description of amino 
acids responsible for hydrogen bond formations and for hydrophobic interactions is given in Figure 
31.  
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Figure 30. Targeting phosphoinositide 3-kinase (PI3K) with small molecule ATP-competitive inhibitors. (A-F) Surface 
diagram of ATP·PI3K crystal structures zoomed into the ATP-binding site. Amino acids residues and the ligands are 
represented in stick form, colored according to the element (C atoms in grey, N atoms in blue, O atoms in red and S atoms 
in yellow). Numbers denote highlighted, prominent side chains mediating PI3K/ligand interactions; in green are colored 
amino acids for which hydrophobic contacts with the ligand could be obtained. For amino acids such as Asp836, Asp841, 
Glu880, Val882, Asp964, Lys833, and Lys890 both hydrophobic contacts and H-bridge formations could be obtained. Only 
hydrogen bonds that we are confident with are shown as yellow dashed lines. These correspond to the contact list from the 
Figure 31. For MJA40 there is only density for the morpholino group in contact with Val882 leading us to the conclusion 
that MJA40 is not able to reach the binding pocket of PI3K; this observation was comparable with the experimental in vitro 
data and with the in silico data by docking MJA40 into PI3K. For the cellular activity and isoform specificity of the 
depicted inhibitors consult text and data from the chapter “Chemistry and Biology”. 
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Figure 32. Targeting phosphoinositide 3-kinase (PI3K) with small molecule ATP-competitive inhibitors. (A-F) Extracted 
amino acids mediating PI3K/ligand interactions within the ATP-binding site; the electron density map of the compounds is 
presented in magenta mesh. Only hydrogen bonds that we are confident with are shown as black dashed lines. 
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The available crystal structures of PI3K and PI3Kα from the Protein Data Bank were used for 
molecular modelling experiments. Three dimensional model of mTOR was created based upon the 
crystal structure of p110. The models were constructed as outlined by Pirola et al. [31]. For the 
docking studies, we used the genetic algorithm application GOLD [32]. Compounds were docked 
into the crystal structures and homology model by optimizing conformational and non-bonded 
contacts. The default scoring functions in GOLD are GoldScore and ChemScore; after an initial 
examination of LY294002 to compare the docked compound in p110 to its X-ray structure, we 
elected to use GoldScore to dock the compounds, which produced nominally better results. 
Compound orientations using GOLD and GoldScore were generated and saved, and the highest-
scoring orientation that also formed plausible hydrogen bond interactions was selected. The docked 
ligand and receptor structures were subsequently subjected to minimization and dynamics using the 
program Yasara and the Yamber forcefield. This was conducted mainly to relieve close contacts 
within the protein to the ligand, and to determine whether any of the docked compounds would be 
“ejected” from the pocket. Minimization and dynamics cycles were performed until the 
conformations of both the ligand and protein remained unchanged, and none of the docked 
compounds were “ejected”. 
To establish whether the docking results were enough authentic, we compared the data with the 
corresponding crystal structures of PI3K complexed with the molecules from the matrix-template 
library. Analysis of the docked and crystal structures confirmed similar compound orientations, 
with the same hydrogen bonds being formed between the compounds and the ATP pocket in the 
protein (Figure 33).  
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Figure 33. Targeting phosphoinositide 3-kinases (PI3Ks). (A-E) Comparison of the x-ray ligands (colored according to 
element) and docked ligands (colored in blue) in PI3K (ribbon representation in gray). (A’-E’) Docked ligands 
(colored according to element) in PI3Kα (ribbon representation in light blue). (A-A’) Ligand ASA76 docked in PI3K 
and PI3Kα in similar fashion. The binding mode of the docked structure of ASA76 is similar to the binding mode of the 
x-ray structure in PI3K. (B-B’) Ligand ZSTK474 docked in PI3K and PI3Kα also in similar fashion. The binding 
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mode of the docked structure of ZSTK474 is similar to the binding mode of the x-ray structure in PI3K. (C-C’) The 
docked structure of the ligand NCB36 in PI3K was planar and in PI3Kα was similar to the x-ray structure in PI3K. 
(D-D’) The PI3K docking corresponds well with the x-ray structure, in PI3Kα the compound is flipped (in all 10 
docked conformations), probably while the morpholine binding to the HingeVal is conserved to the other morpholine 
and the aminopyrimidine fragment is flipped to the hydrophobic pocket 2. This could be due to the different residues 
found in alpha versus gamma isoforms. (E-E’) NCB5 docked in PI3K in similar fashion compared to the x-ray 
structure. In all 10 docked orientations in PI3Kα, none of them have the second morpholine residue in the same 
orientation, even though the trifluoromethyl group comes close to that found in PI3K. (F-F’) MJA40 docks in the same 
orientation with the morpholine but the indole moiety flips round in all the docked structures; in PI3Kα the compound is 
rotated, where the indole moiety is facing the hydrophobic pocket II; this fragment is flipped towards the hydrophobic 
pocket 2. This could be due to the difference between an alpha and a gamma pocket. 
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Figure 34. (A-E) Comparison of the x-ray ligands (stick forms and colored according to element) and docked 
ligands (line forms) in PI3K. (A’-E’) Comparison of the x-ray ligands (stick forms and colored according to 
element) and docked ligands (line forms) in PI3Kα. 
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Figure 35. Designing the 3D structure of mTOR and its comparison with PI3Kα. A ribbon diagram of mTOR 
model (blueish), based on PI3K, and superimposed on PI3Kα (pinkish) is presented. A relatively fast but 
detailed analysis shows a lot of differences between PI3Kα and mTOR, some of which are conducive to explain 
the difference of affinity between PI3Kα and mTOR for ligand MJA40 (thick lines). Also a picture of alignment 
between alpha and mTOR, where blue ovals show important differences, is presented. MJA40 was docked in 
mTOR (gold score of 75.9) and in PI3Kα (gold score 56.0) presenting much stronger affinity to mTOR, 
confirmed also by experimental IC50 estimation (IC50 (PI3Kα) = 500 nM).  
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4. Chemistry and Biology 
 
4.1. Pyridinylfuropyrimidine Derivatives 
 
The commercial available starting material 2-chloropyridine-3-carbonitrile (1) was treated with 
ethyl glycolate under basic conditions in the presence of 3-methylbutanol, where the 
aminofuropyridine 2 (AS3) was obtained. Amide formation of 2 with 3-methoxybenzoyl chloride 
yielded the furopyridine 3 (AS7). Further ester hydrolysis of 3 and directly amide formation with 
methanolic ammonia yielded the amide 4, which was cyclized under basic conditions to the 
pyrimidinone 5 (AS18). Cleavage of the methyl group under acidic conditions, and further 
protection of the phenol group with acetic anhydride yielded the pyrimidinone 7 (AS21). Further 
treatment with phosphorus oxychloride (POCl3) gave the chlorinated pyrimidine 8 (AS24), which 
was further substituted on the chlorine position with different secondary amines indicated in Table 
5.  
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Scheme 2. 
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Reagents and conditions: (a) ethyl glycolate (1.1 eq.), Na2CO3 (2.0 eq.), 3-methylbutanol, reflux, 72 
h, 31%; (b) 3-methoxybenzoyl chloride (1.1 eq.), Et3N (1.1 eq.), CH2Cl2, room temp., 28 h, 86%; 
(c) NH3(sat.), MeOH, room temp., 4 h, 100%; (d) 5% NaOH(aq.) (10 eq.), EtOH, reflux, 1 h, 90%; (e) 
AcOH(conc.), HBr(conc.), reflux, 8 h, 100%; (f) Ac2O (~100 eq.), Et3N (1.6 eq.), reflux, 1 h, 42%;  (g) 
POCl3 (100 eq.), reflux, 3 h,100%; (h) amine (2.2-3.5 eq.), n-butanol, 105 °C, 4-72 h, 6-85%.
a) b)
c)
d)e)
f)
g) h)
1 2
3
4
56
7 8
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Table 5. 
N
N
O
N
R1
OH
 
In cell inhibition 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R1 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++++ ++++ 
9 (PI103) 
*
N
O
 
20 
+++ +++ 
(+) ++(+) 
10 (AS44) 
*
N
S
 
51 
+ ++ 
- ++(+) 
11 (VCC17) 
*
N
O
 
74 
- +++ 
- +(+) 
12 (VCC16) 
*
N
O
 
99 
- ++ 
- - 
13 (VCC3) 
*
N
O
 
116 
- - 
- - 
14 (AS38) 
N
N
*  
89 
- - 
- - 
15 (AS47) N
N
*  
92 
- - 
- - 
16 N
*  
ND 
- - 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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4.2. Benzofuropyrimidine Derivatives 
 
One of the aims of this project was to investigate the biological activity of 3-(4-
morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol (9, PI103) derivatives, where the 
phenol moiety on the 2-position of the pyrimidine ring is replaced with different isosteric 
heterocycles. Due to the poor water solubility of inhibitor 9 (PI103), we decided to produce and 
biologically characterize an analog of PI103, compound 23 (JBA65), by hopping from 
pyridinylfuropyrimidine scaffold to benzofuropyrimidine scaffold. Compound 3-(4-
morpholinopyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl)phenol 23 (JBA65) was synthesized in a 
similar synthetic fashion as accomplished by 9 (PI103) (Scheme 3). After improved excellent 
biological activity of JBA65, which was comparable with the activity of PI103, and better water and 
DMSO solubility, a new synthetic route was developed, in order to produce 2-chloro-4-
morpholinobenzofuro[3,2-d]pyrimidine 24 (ASA75), where on the 2-chloro position of the 
benzofuropyrimidine 24 different heterocyclic boronic acid pinacol esters were coupled by Suzuki-
Miyaura reaction and different heterocyclic secondary amines by nucleophilic substitution (Scheme 
4). Treatment of 3-aminobenzofuran-2-carboxamide (17) with ethyl chloroformate (Scheme 4) 
afforded the carbamate 21 (ASA82), which was converted into benzofuro[3,2-d]pyrimidine-
2,4(1H,3H)-dione (22) (ASA70) by ring cyclization under basic conditions. Further chlorination of 
22 with phosphorus oxychloride, followed by selective substitution with morpholine on the 4-chloro 
position of the pyrimidine ring, yielded the 2-chloro-4-morpholinobenzofuro[3,2-d]pyrimidine (24) 
(ASA75), which was further substituted on the 2-chloro position under Suzuki conditions. 
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Scheme 3. 
O
NH2
O
NH2
O
O
NH
O
O
NH
N
O
O
O
NH
N
O
O
OH
N
N
O
Cl
OAc
NH
N
O
O
OAc
N
N
O
R2
OH
a)
d)
c)
NH2
b)
e)
f)
Reagents and conditions: (a) 3-methoxybenzoyl chloride (1.1 eq.), Et3N (1.1 eq.), CH2Cl2, room temp., 
18 h, 31%; (b) 5% NaOH(aq.) (10 eq.), EtOH, reflux, 1.5 h, 100%; (c) AcOH(conc.), HBr(conc.) (80 eq.), 
reflux, 8 h, 82%; (d) Ac2O (100 eq.), Et3N (1.6 eq.), reflux, 1.5 h, 100%;  (e) POCl3 (100 eq.), reflux, 4 
h, 29%; (f) amine (2.2-3.5 eq.), n-butanol, 105 °C, 4-72 h, 10-100%.
17
18
19
202122
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Table 6. 
N
N
O
R2
OH
 
In cell inhibition 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R2 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++++ ++++ 
23 (JBA65) 
*
N
O
 
17 
++++ ++++ 
- ++ 
24 (VCC19) 
*
N
O
 
53 
- + 
- (+) 
25 (VCC18) 
*
N
O
 
124 
- +(+) 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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Scheme 4. 
O O
NH2
NH2
O
NH
NH2
O
O
O
O N
N
Cl
Cl
O N
N
N
Cl
O
26
O
N
H
NH
O
O
27
2829
O N
N
N
R3
O
a) b)
c)
d)f) or e)
Reagents and conditions: (a) ethyl chloroformate (1.0 eq.), toluene, reflux, 6 h, 67%; (b) 5% 
NaOH(aq.) (10 eq.), EtOH, reflux, 1 h, 85%; (c) POCl3 (5.0 eq.), DIPEA (5.0 eq.), 100 °C, 22 h, 
52%; (d) morpholine (2.2 eq.), MeOH, reflux, 30 min., 95%; (e) boronic acid pinacol ester (4.0 eq.), 
1,1'-bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane complex (0.025 eq.), 2M 
Na2CO3(aq.):1,2-dimethoxyethane (1:3), reflux, 10-15 h; (f) amine (1.1 eq.), NaH (1.5 eq.), DMF, 
reflux, 4 h.
17
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Table 7. 
O N
N
N
R3
O
 
In cell inhibition 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R3 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
+ ++ 
30 (GSA26) *
 
70 
- + 
+ ++++ 
31 (GSA36) 
*
NH2
 
ND 
- ++++ 
++ ++++ 32 
(GSA39) 
(HGA3) 
* NH2
 
ND 
- ++++ 
+++ ++++ 
33 (ASA99) 
N
*
 
38 
++ ++++ 
++++ ++++ 
34 (ASA76) 
N
* NH2
 
20 
++++ ++++ 
++(+) ++++ 
35 (ASA101) N
* NH
O
 
41 
+ ++++ 
+++ ++++ 
36 (ASA100) 
N
N
*
 
39 
++ ++++ 
+++ ++++ 
37 (ASA98) 
N
N
* NH2
 
20 
++ ++++ 
++++ ++++ 
38 (GSA47) 
N
N
* NH2
H3C
 
ND 
++(+) ++++ 
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Table 7 (continued). 
 
In cell inhibition 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R3 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
+++ ++++ 
39 (ASA78) 
*
N
H  
54 
++ ++++ 
- + 
40 (VVA75) 
*
N
H
CF3
 
100 
- - 
++ ++++ 
41 (ASA79) * NH
 
62 
+ ++++ 
+++ ++++ 
42 (VVA49) 
*
N
H
N
 
8 
++ ++++ 
- - 
43 (VVA73) 
*
N
H
N
F
 
98 
- - 
+ +++ 
44 (VVA79) 
*
N
H
N
F  
47 
- - 
- +++ 
45 (ASA80) * NH
N
 
118 
- - 
- +++ 
46 (ASA81) 
*
N
H
N
 
67 
- - 
+++(+) ++++ 
47 (GSA32) 
N
N
*
CH3
 
ND 
- ++++ 
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Table 7 (continued). 
 
In cell inhibition 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R3 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
- +++ 
48 (ASA92) 
N
N
*
 
80 
- ++ 
+ +++ 
49 (ASA95) 
N
N
*
 
84 
+ ++++ 
- +++ 
50 (ASA94) ON*
 
93 
++ ++++ 
+ +++ 
51 (ASA113) ON*
 
90 
- +++ 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
 
    
Vladimir Cmiljanovic  Targeting lipid signalling in cancer 
-126-
4.3. Thienopyrimidine Derivatives 
 
Scheme 5. 
NH2
S O
O
NH
S O
O
O
O
NH
S NH2
O
O
O
N
S NH
O
O
N
S NH
O
O
O
N
S NH
O
OH
N
S N
Cl
O
O
N
S N
R4
OH
a) b)
c)
d)e)
f)
g)
52
53 54
555657
58 59
Reagents and conditions: (a) Et3N (1.1 eq.), CH2Cl2, 0 °C to room temperature, 3 h, 100%; (b) 
methanolic ammonia (7N), 90 °C, 44 h, steel bomb at 50 psi (3.7 bar), 100%; (c) 5% NaOH(aq.) (10 eq.), 
EtOH, reflux, 1.5 h, 100%; (d) AcOH(conc.), HBr(conc.) (80 eq.), reflux, 8 h, 80%; (e) Ac2O (100 eq.), 
Et3N (1.6 eq.), reflux, 1.5 h, 100%;  (f) POCl3 (100 eq.), reflux, 4 h, 30%; (g) amine (2.2-3.5 eq.), n-
butanol, 105 °C, 4-72 h, 50-80%.
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Table 8. 
N
S N
R4
OH
 
 
In cell inhibition 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R4 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++++ ++++ 
60 (VCB187) 
O
N
*  
15 
+++ +++ 
- - 
61 (VCB192) 
N
*  
87 
- - 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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Scheme 6. 
N
S N
Cl
Cl N
S N
N
Cl
a)
62 63
Reagents and conditions: (a) morpholine (2.2 eq.), methanol, room temperature, 1 h, 100%; (b) 
boronic acid pinacol ester (4.0 eq.), 1,1'-bis(diphenylphosphino)ferrocene-palladium(II) 
dichloromethane complex (0.025 eq.), 2M Na2CO3(aq.):1,2-dimethoxyethane (1:3), reflux, 10-
15 h; (c) amine (1.1 eq.), NaH (1.5 eq.), DMF, reflux, 4 h.
O
N
S N
N
R5
b), c)
O
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Table 9. 
N
S N
N
R5
O
 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R5 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++ +++ 
64 (NCB100) *
 
72 
- ++(+) 
- ++++ 
65 (NCB101) 
*
NH2
 
77 
- ++++ 
++ ++ 
66 (NCB98) 
*
HN S
O
O
 
90 
- ++ 
- - 
67 (VCC33) * NH2
 
98 
- - 
- - 
68 (VCB155) 
*
O
 
52 
- ++(+) 
- - 
69 (VCB201) 
*
O Si
 
43 
- + 
+ ++++ 
70 (NCB67) *
N
 
65 
+ ++++ 
- +++ 
71 (VCC41) *
N
F 
89 
- + 
+ ++++ 
72 (VCC10) *
N
NH2
 
17 
+++ +++ 
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Table 9 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R5 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++ ++++ 
73 (NCB65) 
*
N
NH2
F3C
 
8 
+(+) ++++ 
+(+) +++ 
74 (NCB68) *
N
N
 
33 
- ++(+) 
+++(+) +++(+) 
75 (VCC30) *
N
N
NH2
 
30 
+++ +++ 
- ++++ 
76 (VCC31) 
*
N
H  
76 
+ ++++ 
++ ++++ 
77 (VCC40) * NH
 
90 
+ ++++ 
- + 
78 (MJA19) 
*
N
 
118 
+ + 
(+) ++++ 
79 (NCB102) 
*
N
H
N
 
20 
- ++++ 
+ +++(+) 
80 (VCC34) * NH
N
 
87 
- +++(+) 
- + 
81 (MJA18) 
*
N
H
N
 
112 
+ + 
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Table 9 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R5 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
(+) +++ 
82 (VCC35) 
*
NH
N
 
77 
- +++ 
++ ++++ 
83 (NCB74) 
N
N
*
CH3
 
62 
- +(+) 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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4.4. Di-Morpholine-Containing Triazine Derivatives 
 
Scheme 7 shows a method for selectively displacing of two chlorines from 2,4,6-trichloro-1,3,5-
triazine (69) with morpholine in dimethylformamide to prepare bis-morpholino triazine 
intermediate 70, which was further coupled with heterocyclic boronic acid pinacol esters by Suzuki-
Miyaura reaction and heterocyclic secondary amines by nucleophilic substitution. 
 
Scheme 7. 
NN
N Cl
N
N
N
N
N
Cl
Cl Cl
84 85
O
O
a)
Reagents and conditions: (a) morpholine (4.5 eq.), DMF, 0 °C, 20 min., 56%; (b) boronic acid pinacol 
ester (4.0 eq.), 1,2-dimethoxyethane:2M Na2CO3 (3:1), dichloro 1,1'-bis(diphenylphosphino)ferrocene-
palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 15-20 h; c) amine (1.1 eq.), NaH 
(1.5 eq.), DMF, reflux, 4 h.
NN
N R6
N
N
O
O
b), c)
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Table 10. 
NN
N R6
N
N
O
O  
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R6 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
+(+) ++(+) 
86 (GSA10) *
 
77 
- + 
- - 
87 (NCA197) 
*
N
 
68 
- - 
- - 
88 (NCA201) 
*
N 
87 
- - 
- + 
89 (NCA193) 
*
NH2
 
82 
+ +++(+) 
- +++ 
90 (NCA189) * NH2
 
76 
(+) ++++ 
++ ++++ 
91 (NCA183) 
*
OH
 
26 
+++ ++++ 
+ ++++ 
92 (NCA205) *
N
 
60 
- ++(+) 
- ++ 
93 (NCB9) *
N
F 
97 
- + 
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Table 10 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R6 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
+ ++++ 
94 (NCB90) 
N
*
CH3 
77 
+ ++++ 
(+) + 
95 (NCB89) 
N
*
N 
99 
- - 
- - 
96 (NCA215) 
N
*
N
O 
97 
- - 
- ++++ 
97 (NCA163) *
N
NH2
 
67 
+++ ++++ 
++++ ++++ 
98 (NCB5/NCB63) 
*
N
NH2
F3C
 
20 
+++(+) +++(+) 
- + 
99 (MJA47) *
N
OH
 
121 
+ + 
+ +(+) 
100 (NCB78) *
N
N
 
72 
- - 
+(+) ++ 
101 (NCB95) *
N
N
N
 
38 
+ + 
+++(+) ++++ 
102 (NCB15) *
N
N
NH2
 
11 
++++ ++++ 
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Table 10 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R6 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++++ ++++ 
103 (NCB86) 
*
N
N
NH2
H3C
 
8 
++(+) ++++ 
ND ND 
104 (MZ-043) 
*
N
N
NH2
F3C
 
ND 
ND ND 
+++ ++++ 
105 (MJA7) 
*
N
H  
79 
++(+) ++++ 
+ +++ 
106 (VVA81) 
*
N
H
CF3
 
100 
- + 
+ +++ 
107 (MJA6) * NH
 
110 
+ ++++ 
++(+) ++++ 
108 (MJA46) 
*
N
H
N
 
38 
+ ++++ 
(+) +++ 
109 (VVA103) 
*
N
H
N
F
 
37 
- +++(+) 
++(+) ++++ 
110 (VVA97) 
*
N
H
N
F  
26 
- +++(+) 
+ +++ 
111 (NCB22) * NH
N
 
111 
+ +(+) 
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Table 10 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R6 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
- +(+) 
112 (MJA14) 
*
N
H
N
 
119 
+(+) ++ 
++ ++++ 
113 (MJA44) 
*
N
H
N
 
61 
+ ++++ 
++++ ++++ 
114 (NCB53) 
N
N
CH3
*
 
53 
+(+) ++++ 
++++ ++++ 115 
(NCA110/NCB38/ 
ZSTK474) 
N
N
*
F
F
 
13 
+++(+) +++(+) 
++ ++++ 
116 (NCA111) 
N
N
*
F
F
F
 
25 
+ +++ 
+ ++ 
117 (NCB82) N
CH3
*
 
92 
- (+) 
+ ++++ 
118 (NCA77) 
N
N
*
 
69 
+ +++(+) 
- + 
119 (NCA152) N
*
 
86 
- + 
- + 
120 (NCA181) 
N
N
*
 
89 
- ++ 
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Table 10 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R6 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
- + 
121 (NCA173) 
N
N
*
 
65 
- ++(+) 
++ +++ 
122 (BAS02828052) 
N
N
*
 
96 
- +(+) 
+++(+) ++++ 
123 (NCB94) 
N
N
*
Cl
 
28 
+(+) +++ 
+(+) ++++ 
124 (BAS01056850) 
OH
HN
*
 
77 
- +++ 
- - 
125 (MJA12) ON*
 
116 
- - 
- - 
126 (MJA32) ON*
 
126 
- - 
- +(+) 
127 (ASN09891537) N
F
N
*
 
128 
- - 
+(+) - 
128 (BAS07354380) 
CF3
HN
*
 
103 
- - 
+(+) - 
129 (7927373) 
CF3
O
*
 
99 
- - 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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4.5. ZSTK474 Derivatives 
 
Scheme 8. 
NN
N Cl
N
Cl
N
N
N
Cl
Cl Cl
130
O
a)
Reagents and conditions: (a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 20 min., 28%; (b) K2CO3,  (1.5 
eq.), 2-difluoromethyl-1H-benzoimidazole (1.4 eq.), DMF, 30 min. at 0 °C, 4 h at room temp., 65%; 
(c) boronic acid pinacol ester (4.0 eq.), 1,2-dimethoxyethane:2M Na2CO3 (3:1), dichloro 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.025 eq.), 90 °C, 
15-20 h; d) amine (1.1 eq.), NaH (1.5 eq.), DMF, reflux, 4 h.
NN
N N
N
Cl
O
b)
N
F
F84
131
NN
N N
N
R7
O
N
F
F
c), d)
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Table 11. 
NN
N N
N
R7
O
N
F
F
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R7 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
ND ND 
132 
ON*
 
ND 
ND ND 
ND ND 
133 
ON*
 
ND 
ND ND 
ND ND 
134 ON*
 
ND 
ND ND 
ND ND 
135 ON*
 
ND 
ND ND 
ND ND 
136 ON*
 
ND 
ND ND 
+++(+) ++++ 
137 (NCB87) NN*
 
34 
+ ++++ 
++++ ++++ 
138 (NCB37) N*
 
39 
+(+) ++++ 
++++ ++++ 
139 (NCB36) NN*
 
33 
++++ ++++ 
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Table 11 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R7 In vitro PI3Kalpha inhibition at 200nM 
pS6 
1 µM 
pS6 
10 µM 
++ ++++ 
140 (NCB91) SN*
O
O 
34 
- +++(+) 
++++ ++++ 
141 (NCB60) NN* S
O
O
 
17 
++++ ++++ 
++++ ++++ 
142 (NCB57) NN* S
O
O
 
35 
(+) +++ 
- - 
143 (NCB48) *
CF3
CF3 
115 
- - 
+(+) ++ 
144 (NCB51) 
* F
F  
31 
- (+) 
++ ++++ 
145 (NCB49) 
*
N
O
 
41 
- +++(+) 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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4.6. Di-Morpholine-Containing Pyrimidine Derivatives 
 
Scheme 9. 
N
N
Cl
Cl Cl
N
N
N
N Cl
O
O
N
N Cl
N
Cl
O
N
N
N
N Cl
O
O
N
N
N
N R8
O
O
N
N R8
N
R9
O
N
N
N
N R8
O
O
a)
b)
c)
d)
146
147
148
149
Reagents and conditions: (a) morpholine (2.5 eq.), N,N-diisopropylethylamine (3.0 eq.), ethanol, 0 °C to 
room temperature, 16 h, mixture of 132 and 133 (7:1); (b, c, d) boronic acid pinacol ester (4.0 eq.), 1,1'-
bis(diphenylphosphino)ferrocene-palladium(II) dichloromethane complex (0.025 eq.), 2M Na2CO3(aq.):1
dimethoxyethane (1:3), reflux, 10-15 h; (c) amine (1.1 eq.), NaH (1.5 eq.), DMF, reflux, 4 h.
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Table 12. 
N
BA
N
N R8
O
O
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R8 A B 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
- - 
150 
(GSA22) *  
C N 87 
- - 
- + 
151 
(GSA23) *
NH2
 
C N 93 
- - 
- + 
152 
(GSA24) * NH2 
C N 84 
- - 
++ ++++ 
153 
(VVA105) *
OH
 
C N 30 
- +++(+) 
+(+) ++(+) 
154 
(VVA107) *
N
 
C N 81 
+(+) +++ 
++(+) ++++ 
155 
(VVA111) *
N
NH2
 
C N 63 
+++ ++++ 
++(+) +++ 
156 
(VVA109) *
N
N
 
C N 72 
+ +++ 
+++ +++(+) 
157 
(VVA113) *
N
N
NH2
 
C N 49 
+(+) ++++ 
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Table 12 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R8 A B 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
++(+) ++++ 
158 
(VVA131) *
N
N
NH2
H3C
 
C N 24 
+++ ++++ 
ND ND 
159 
(ND) *
N
N
NH2
F3C
 
C N ND 
ND ND 
++(+) +++ 
160 
(VVA119) 
*
N
H  
C N 98 
+++(+) ++++ 
++ +++(+) 
161 
(VVA123) * NH
 
C N 91 
+++(+) ++++ 
++(+) +++(+) 
162 
(VVA117) 
*
N
H
N
 
C N 42 
+++ ++++ 
++ ++ 
163 
(VVA115) * NH
N
 
C N 97 
+++ +++ 
++(+) +++(+) 
164 
(NCB106) 
N
N
*
CH3
 
C N 53 
- +++ 
++++ ++++ 
165 
(NCB35) 
N
N
*
F
F 
C N 11 
++++ ++++ 
+++ ++++ 
166 
(NCB34) 
N
N
*
F
F
F
 
C N 36 
+ +++ 
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Table 12 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R8 A B 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
- +(+) 
167 
(GSA20) *  
N C 78 
+ ++ 
- - 
168 
(NCA195) 
*
N
 
N C 85 
- - 
- - 
169 
(NCA199) * N 
N C 97 
- - 
- + 
170 
(NCA191) *
NH2
 
N C 73 
- ++ 
- + 
171 
(NCA187) * NH2 
N C 87 
+ +++(+) 
(+) ++++ 
172 
(NCA185) *
OH
 
N C 57 
++ +++(+) 
- + 
173 
(NCA203) *
N
 
N C 75 
- - 
+ +++ 
174 
(NCB11) 
*
N
F 
N C 117 
- + 
- - 
175 
(NCA207) * N 
N C 93 
- - 
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Table 12 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R8 A B 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
- +(+) 
176 
(ASA89) 
N
*
N
O 
N C 123 
- - 
- ++++ 
177 
(NCA165) *
N
NH2
 
N C 51 
++ ++(+) 
+++(+) ++++ 
178 
(NCA235) *
N
NH2
F3C
 
N C 15 
+ ++ 
+ ++ 
179 
(GSA28) *
N
N
 
N C 60 
- - 
++(+) ++++ 
180 
(NCB16) *
N
N
NH2
 
N C 18 
+++(+) ++++ 
++++ ++++ 
181 
(NCB115) *
N
N
NH2
H3C
 
N C 30 
+ ++++ 
ND ND 
182 
(ND) *
N
N
NH2
F3C
 
N C ND 
ND ND 
++ ++++ 
183 
(NCB20) 
*
N
H  
N C 86 
+ ++++ 
+ ++++ 
184 
(NCB19) * NH
 
N C 105 
++ ++++ 
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Table 12 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R8 A B 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
- ++++ 
185 
(GSA21) 
*
N
H
N
 
N C 46 
++ ++++ 
+ ++ 
186 
(ASA87) * NH
N
 
N C 105 
(+) (+) 
- +(+) 
187 
(ASA88) 
*
N
H
N
 
N C 114 
- - 
- ++ 
188 
(GSA29) 
N
N
*
CH3
 
N C 64 
- ++++ 
+ ++++ 
189 
(NCA169) 
N
N
*
 
N C 63 
+ +++ 
ND ND 
190 
(ND) 
N
N
*
F
F 
N C ND 
ND ND 
- + 
191 
(NCA171) 
N
N
*
 
N C 66 
+ ++ 
+(+) +(+) 
192 
(ASA102) * N O 
N C 107 
- - 
+(+) +(+) 
193 
(ASA108) * N O
 
N C 107 
- - 
- - 
194 
(ASA110) * N N  
N C 123 
- - 
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Table 12 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R8 A B 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
- - 
195 
(ASA109) * N  
N C 117 
- - 
- - 
196 
(ASA111) * N NH 
N C 134 
- - 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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4.7. Linked Triazine and Pyrimidine Derivatives 
 
Scheme 10. 
NN
N Cl
N
Cl
N
N
N
Cl
Cl Cl
130
O
a)
Reagents and conditions: (a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 1 h, 41% 130 (MJA34); (b) 2-
pyridylcarbinol (1.4 eq.), NaH (1.0 eq.), THF, room temperature, 2 h, 46% 197 (MJA33/35/36); (c) 2-
picolylamine (1.1 eq.), CH2Cl2, room temperature, 21 h, 23% 198 (MJA11/17/22); (d) 3-picolylamine 
(1.5 eq.), CH2Cl2, - 5 °C, 16 h, 33% 199 (HGA12); (e) boronic acid pinacol ester (4.0 eq.), 1,2-
dimethoxyethane:2M Na2CO3 (3:1), dichloro 1,1'-bis(diphenylphosphino)-ferrocene-palladium(II)-
dichloride dichloromethane complex (0.025 eq.), 90 °C, 15-20 h; f) amine (1.1 eq.), NaH (1.5 eq.), 
DMF, reflux, 4 h.
NN
N Cl
N
X
O
b), c), d)
84
e), f)
Y
Z
NN
N R9
N
X
O
Y
Z
197, X = O; Y = N; Z = C
198, X = NH; Y = N; Z = C
199, X = NH; Y = C; Z = N
X = O; Y = N; Z = C
X = NH; Y = N; Z = C
X = NH; Y = C; Z = N
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Table 13. 
NN
N R9
N
X
O
Y
Z
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R9 X Y Z 
In vitro 
PI3Kalpha 
inhibition 
at 200nM pS6 
1 µM 
pS6 
10 µM 
- - 
200 
(NCB107) *  
O N C 86 
- - 
++ ++ 
201 
(NCB108) *
NH2
 
O N C 87 
- +(+) 
- ++(+) 
202 
(NCB109) * NH2 
O N C 88 
- - 
++(+) ++++ 
203 
(MJA43) *
OH
 
O N C 51 
+ ++++ 
++ ++(+) 
204 
(MJA39) *
N
 
O N C 91 
- - 
++ ++(+) 
205 
(MJA38) *
N
NH2
 
O N C 76 
- ++ 
+ + 206 
(GSA33) 
(HGA1) 
*
N
N
 
O N C 89 
- - 
+ +++ 
207 
(MJA37) *
N
N
NH2
 
O N C 45 
+ ++++ 
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Table 13 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R9 X Y Z 
In vitro 
PI3Kalpha 
inhibition 
at 200nM pS6 
1 µM 
pS6 
10 µM 
++++ ++++ 
208 
(MJA40) 
*
N
H  
O N C 65 
++ ++++ 
(+) +++ 
209 
(VVA77) 
*
N
H
CF3
 
O N C 99 
- - 
+ +++ 
210 
(MJA42) 
*
N
H  
O N C 107 
+ ++++ 
- +++ 
211 
(MJA60) 
N
H
N
*
 
O N C 84 
+ ++(+) 
- - 
212 
(VVA101) 
N
H
N
*
F
 
O N C 103 
- - 
- - 
213 
(VVA95) 
N
H
N
*
F  
O N C 100 
- - 
+(+) ++(+) 
214 
(MJA41) * NH
N
 
O N C 100 
- + 
- + 215 
(GSA31) 
(HGA2) 
N
N
*
CH3
 
O N C 90 
++ ++++ 
+ +++ 
216 
(MJA25) *
OH
 
NH N C 66 
- +++ 
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Table 13 (continued). 
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R9 X Y Z 
In vitro 
PI3Kalpha 
inhibition 
at 200nM pS6 
1 µM 
pS6 
10 µM 
- - 
217 
(MJA29) *
N
 
NH N C 123 
- - 
+ + 
218 
(MJA30) *
N
NH2
 
NH N C 71 
- +++ 
+ +++ 
219 
(MJA31) *
N
N
NH2
 
NH N C 40 
+(+) ++++ 
+ +++ 
220 
(MJA28) 
*
N
H  
NH N C 104 
- ++ 
- +(+) 
221 
(MJA26) * NH
 
NH N C 123 
- - 
- - 
222 
(MJA27) * NH
N
 
NH N C 125 
- - 
- (+) 223 
(GSA59) 
(HGA13) 
*
 
NH C N 98 
- - 
- - 
224 
(HGA14) *
N
NH2
 
NH C N 67 
- +++(+) 
+ +++(+) 
225 
(HGA15) *
N
N
NH2
 
NH C N 19 
- +++(+) 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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Scheme 11. 
NN
ClCl
Cl
BA
D Cl
N
X
O
N
BA
D Cl
Cl
X
N
226, X = O; A= N; B = N; D = C
227, X = NH; A = N; B = N; D = C
228, X = NH; A = N; B = C; D = N
a), b) c), d), e)
229, X = O; A= N; B = N; D = C
230, X = NH; A = C; B = N; D = N
231, X = NH; A = N; B = C; D = N
f), g)
Reagents and conditions: (a) 2-pyridinemethanol (1.0 eq.), NaH (1.0 eq.), THF, room temperature, 3 h, 
26% 226 (JBA133); (b) 2-aminomethylpyridine (1.1 eq.), DIPEA (1.1 eq.) dioxane, room temperature, 
2 h, mixture of 227 (JBA113A) and 228 (JBA113B) (2:1); (c) 226 (JBA133) (1.0 eq.), morpholine (1.5 
eq.), DIPEA (1.5 eq.), dioxane, room temperature, 2 h, 63% 229 (JBA147); (d) 227 (JBA113A) (1.0 
eq.), morpholine (1.8 eq.), DIPEA (1.5 eq.), dioxane, reflux, 5 h, 84% 230 (JBA123); (e) 228 
(JBA113B) (1.0 eq.), morpholine (1.5 eq.), DIPEA (1.5 eq.), dioxane, room temperature, 2 h, 71% 231 
(JBA125); (f) boronic acid pinacol ester (4.0 eq.), 1,2-dimethoxyethane:2M Na2CO3 (3:1), dichloro 
1,1'-bis(diphenylphosphino)-ferrocene-palladium(II)dichloride dichloromethane complex (0.025 eq.), 
90 °C, 15-20 h; (g) amine (1.1 eq.), NaH (1.5 eq.), DMF, reflux, 4 h.
BA
D R10
N
X
O
N
146
X = O; A= N; B = N; D = C
X = NH; A = C; B = N; D = N
X = NH; A = N; B = C; D = N
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Table 14. 
BA
D R10
N
X
O
N
 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R10 X A B D 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
- ++ 
232 
(JBA155) *
NH2
 
O N N C 124 
(+) (+) 
- +(+) 
233 
(JBA153) * NH2 
O N N C 127 
(+) (+) 
++ ++++ 
234 
(JBA139) *
OH
 
O N N C 31 
- +++ 
- +(+) 
235 
(JBA157) *
N
 
O N N C 109 
(+) (+) 
+ +++ 
236 
(JBA151) *
N
NH2
 
O N N C 66 
- +++ 
+ ++++ 
237 
(JBA149) *
N
N
NH2
 
O N N C 19 
+(+) ++++ 
+ ++ 
238 
(NCB21) * NH
 
O N N C 84 
+ + 
- ++(+) 
239 
(JBA129) *
OH
 
NH C N N 103 
- +++ 
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Table 14 (continued). 
In cell inhibitiona 
pPKB/PKB 
1 µM 
pPKB/PKB 
10 µM Compds R10 X A B D 
In vitro 
PI3Kalpha 
inhibition at 
200nM pS6 
1 µM 
pS6 
10 µM 
+ ++++ 
240 
(JBA141) *
N
NH2
 
NH C N N 62 
++ ++++ 
- ++ 
241 
(JBA131) *
OH
 
NH N C N 88 
+ + 
- - 
242 
(JBA143) *
N
NH2
 
NH N C N 123 
- - 
aInhibitor efficacy and their cell permeability were measured by in cell Western inhibition assay on melanoma cell line 
A2058; “-“ no activity, “+”/“++” poor activity; “+++” good activity; “++++” very good activity; in vitro PI3Kalpha 
inhibition was measured by Kinase Glo assay; given numbers represent %remaining activity, the smaller the value is the 
stronger is the inhibition. 
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4.8. Spirocyclic Oxetane Derivatives 
 
Due to the practical interest in view of its structural relationship to morpholine, we examined the 
biological properties of 2-oxa-6-azaspiro[3.3]heptane (spirooxetane, 261) derivatives. Spirooxetane 
261 was prepared by a recently published procedure of Wuitschick and colleagues [28]. 
Tribromopentaerythritol (243) provides ready access to 2-oxa-6-azaspiro[3.3]heptane (261), which 
can be stored conveniently as its stable oxalate salt 245. Deprotonation of 245 with sodium hydride 
and the nucleophilic substitution with cyanuric chloride provided monosubstituted cyanuric chloride 
derivative 246. Further displacement of chlorine with benzimidazole derivatives provided 247 and 
248. The last nucleophilic substitution of triazine derivatives 247 and 248 with different piperazine 
derivatives yielded the asymmetric end-products of Scheme 12. We observed that the nucleophilic 
substitution of cyanuric chloride with three different secondary amines could be obtained 
selectively under specific mild conditions. Collectivelly, this access route offers convenient 
pathway to diverse spirooxetane containing triazine libraries.  
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Scheme 12. 
OH Br
Br Br
O
N
SO O
a)
O
N
H2
b)
C2O42-
2
N
N
N
Cl
ClN
O
c)
N N
NCl N
N
O
NR11
N N
NR12 N
N
O
NR11
e)
d)
R11 = -CH3, 247
R11 = -CHF2, 248
Reagents and conditions: (a) p-tosylamide (1.2 eq.), KOH (3.2 eq.), ethanol, reflux, 93 h, 63%; (b) Mg 
granulate (7.0 eq.), MeOH, ultrasound, 1 h, then H2C2O4 (0.5 eq.), 75%; (c) NaH (2.0 eq.), room 
temperature, overnight, 86%; (d) K2CO3 (1.4 eq.), benzimidazole (1.4 eq.), DMF, 4 h, room temperature; 
(e) K2CO3 (3.2 eq.), piperazine (1.2 eq.), DMF, 2 h, room temperature.
R12 = N N
N N
*
*
S
O
O
243
244
245
246
249, R11 = -CH3,
250, R11 = -CHF2, R12 = N N *S
O
O
R12 =251, R11 = -CH3,
N N *R12 =252, R11 = -CHF2,
R12 =253, R11 = -CH3,
R12 =254, R11 = -CHF2, O N *
O N *
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The highly active lipid kinase inhibitor 257 (GSA44) was synthesized through a short three-step 
sequence (Scheme 13) in a same way as done by asymmetric ZSTK474 derivatives from the 
Scheme 8.  
 
Scheme 13. 
N
N
N
N
NN
O
O
N
R11
R11 = -CH3, 256
R11 = -CHF2, 257
NN
N Cl
N
Cl
N
N
N
Cl
Cl Cl
130
O
a)
Reagents and conditions: (a) morpholine (1.0 eq.), CH2Cl2, -50 °C, 20 min., 28%; (b) K2CO3,  (1.5 eq.), 
benzoimidazole (1.4 eq.), DMF, 30 min. at 0 °C, 4 h at room temperature; (c) K2CO3 (3.2 eq.), 2-oxa-
azaspiro[3.3]heptane (0.6 eq.), DMF, room temperature, 3 h.
NN
N N
N
Cl
O
b)
NR1184
R11 = -CH3, 255
R11 = -CHF2, 131
c)
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With the aim to proof the activity of the pyrimidine containing analog of 234 (GSA44), a similar 
synthesis as performed by triazine 234 (GSA44) is presented in Scheme x. The 2,4,6-
trichloropyrimidine (131) was firstly substituted with 2-(difluoromethyl)-1H-benzo[d]imidazole at 
2-chloro position of the pyrimidine ring. Further nucleophilic substitutions with the spirooxetane 
261 and morpholine led to the desired analog of 234 (GSA44), compound 240 (GSA81). The 
systematic biological profiling of this compound is currently under investigation. 
 
Scheme 14. 
N
N ClCl
Cl
N
N NCl
Cl
N
N
N NN
R
N
O
N
N
N
N
N N
O
O
a) b)
c)
260, R = Cl
261, R = morpholine
146 258
259
Reagents and conditions: (a) K2CO3 (1.74 eq), 2-(difluoromethyl)-1H-benzo[d]imidazole (0.9 eq.), 
DMF, 30 min. at - 5 °C and then 18 h at room temperature, 70%; (b) K2CO3 (2.8 eq.), 2-oxa-6-
azaspiro[3.3]heptane (1.0 eq.), DMF, 30 min. at -5 °C and then 18 h at room temperature, 41% 261,
19% 259.
F F
F F
F F
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5. Summary and Outlook 
 
The pharmaceutical development of PI3K inhibitors has made a great leap forward during the 
last 5 years. Promising molecules have entered clinical trials for cancer therapy, inflammation and 
coronary heart disease. First inhibitors with some isoform specificity have been lanced. While 
inhibitor selectivity is often impressive in vitro, in vivo selectivity, potency and efficacy will have to 
be united and improved for chronic treatment of non-fatal diseases, e.g. in inflammation and 
allergy. For some of the pan-PI3K developed for cancer therapy (e.g. BEZ235, PI-103, SF1126, 
XL765, XL147, ZSTK474), encouraging toxicity data has become available. Many experimental 
drugs are relatively well tolerated, even though the molecules cross-react with the whole PI3K 
family and PI3K-related kinases. As drug targeting of PI3K progresses, academia should close the 
gaps in knowledge of the specific function of the different PI3K isoforms. The race to occupy 
niches and markets in PI3K-directed therapies is on. 
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6. Experimental Part 
 
6.1. Conditions of Measurements 
 
Analytical thin layer chromatography (TLC) plates from Merck were used for reaction control 
(silica gel 60 on aluminium sheets) and chromatographic analysis (silica gel 60 on glass). Silica gel 
60 (Fluka) was used for silica gel flash column chromatography. Preparative column 
chromatography employing silica gel was performed according to the method of Still.  
 
Infrared spectra (IR) were recorded on a Perkin-Elmer 1420 spectrophotometer. Absorbance 
frequencies are reported in reciprocal centimeters (cm-1). 
 
Proton nuclear magnetic resonance (1H NMR) spectra and carbon-13 nuclear magnetic 
resonance (13C NMR) spectra were recorded on Bruker spectrometers (Avance400: 400 MHz for 
1H and 101 MHz for 13C; Avance DRX500: 500 MHz for 1H and 125 MHz for 13C; Avance 
DRX600: 600 MHz for 1H and 150 MHz for 13C) at ambient temperature in the solvents indicated, 
and referenced to the residual solvent signal: CDCl3 (7.26), DMSO-d6 (2.50) or CD3OD (3.31) for 
1H chemical shifts and CDCl3 (77.0), DMSO-d6 (39.0) or CD3OD (49.0) for 13C chemical shifts. 
Chemical shifts are reported in  (ppm). Coupling constants are reported in Hertz (Hz). The 
following abbreviations are used: s (singlet), s, br (broad singlet), d (doublet), t (triplet), q (quartet) 
and m (multiplet). 13C NMR spectra were routinely run with broadband decoupling. 
 
Mass Spectrometry Electron Ionization (MS-EI) and Fast Atom Bombardment (MS-FAB) 
spectra were recorded on a VG70-250 (EI) and a MAT 312, using 3-nitrobenzyl alcohol as a matrix 
(FAB). Mass Spectrometry Electron Spray Ionisation (MS-ESI) spectra were recorded in 
methanol on a Finnigan MAT LCQ spectrometer. High Resolution Mass Spectrometry (HR-MS) 
was performed by the mass service at the University of Fribourg (CH). Mass signals are given in 
mass units per charge. The fragments and intensities are given in brackets. 
 
Elemental Analyses (EA) were carried out on a Leco CHN-900 device. The values are given in 
mass percent. 
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6.2. Proliferation Assay 
 
A2058 melanoma cells were plated in a black 96 well plate (7.103 cells/cm2). The next day the cells 
were exposed to different inhibitors at 1mM. Cell numbers were evaluated 1, 2 and 3 days after 
inhibitor treatment with Alamar Blue. Alamar Blue at a final concentration of 10% was added to the 
medium and the plate was left in the incubator for 4 hours. Then fluorescence was measured at an 
excitation wavelength of 560 nm and emission wavelength of 590 nm. The background value (well 
with no cells) was subtracted form all the values and the percentage of cell number compared to the 
control (DMSO treated cells) was calculated. 
 
6.3. Western blot and IC50 determination 
 
Melanoma cells were plated (7.103 cells/cm2), and NVP-BEZ235 and NCA235 (both at 1 mM) were 
added 24 hours later. After 3 hours of exposure to inhibitors, cells were lysed in NP-40-based lysis 
buffer (pH 8.0, 20 mM TrisHCl, 138 mM NaCl, 2.7 mM KCl, 5% glycerol, 1 mM CaCl2, 1 mM 
MgCl2, 1% NP-40, 20 mM leupeptin, 18 mM pepstatin, 1 mM Na-O-vanadate, 20 mM NaF and 100 
mM PMSF). Proteins were separated on SDS-PAGE and transferred to Immobilon FL membranes 
(Millipore). Primary antibodies to pSer473-PKB/Akt and pThr389-p70S6K were from Cell signaling 
Technology (Danvers, MA); to pMAPK and MAPK from Sigma (St. Louis, Missouri), to PKB was 
a kind gift of E. Hirsch (Torino, Italy). Secondary antibodies (e.g. horseradish peroxidase-
conjugated rabbit anti-mouse IgG (Sigma)) were visualized using enhanced chemiluminescence 
(Millipore), and fluorescent secondary antibodies (Alexa Fluor 680 or IRDye 800) were detected 
using the Odysee IR reader (LICOR). 
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6.4. Crystallization and Inhibitor Soaks 
 
ΔABDp110γ crystals were obtained by the sitting-drop vapour diffusion method at 17˚C in the 
presence of 16% PEG 4000, 250mM (NH4)2SO4 and 100mM Tris pH7.5. The crystals reached their 
maximum size (0.2 mm × 0.1mm × 0.1mm) in about 10 days.  
 
The inhibitors NCB5, NCB15 and NCB36 were prepared in DMSO and diluted in cryoprotectant 
containing 25% PEG 4000, 15% glycerol, 250mM (NH4)2SO4 and 100mM Tris pH7.5 to a final 
concentration of 1mM. The inhibitors ASA76 and MJA40 were prepared in DMSO and diluted in 
cryoprotectant consisting of 20% PEG 4000, 20% DMSO, 250mM (NH4)2SO4 and 100mM Tris 
pH7.5 to a final concentration of 1mM. The inhibitor in cryoprotectant solution was added to the 
drop containing the crystals in a stepwise manner. The crystals were soaked in the final 1mM 
inhibitor solution for 3 hours (ASA76, MJA40), 4 hours (NCB15, NCB5, NCB36) or 16 hours 
(ZSTK474). Crystals were then transferred to fresh inhibitor in cryoprotectant solution for 30 
seconds and flash frozen in liquid nitrogen.  
 
6.4.1. Data collection and structure determination 
 
Diffraction datasets were collected at the ESRF beamlines ID23-1 and ID29. Images were 
processed using Mosflm [33] or XDS [34] and scaled with SCALA [35].  
 
The crystal structure of ΔABDp110γ/NCB5 complex was solved by molecular replacement using 
Phaser [36] with the previously published human ΔABDp110γ as the search model (PDB entry 
1E8Y) and subsequent refined using Refmac [37]. Coot was used to manually build inhibitors in the 
unaccounted Fo-Fc difference electron density within the active site of the map [38]. Initial models 
of the inhibitors were generated using the PRODRG server 
(http://davapc1.bioch.dundee.ac.uk/prodrg) [39]. Refmac refinement was iterated with manual re-
building using Coot until the structure converged. 
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6.5. Chemical Synthesis 
 
6.5.1. Materials, Solvents and Reagents 
 
All reactions were performed under an atmosphere of argon and stirred magnetically in oven-dried 
glassware. Anhydrous solvents were transferred via oven-dried syringe or cannula. Tetrahydrofuran 
(THF), dimethoxyethane (DME), diisopropylamine, triethylamine, diisopropylethylamine, 
dimethylsulfoxide, acetonitrile, hexane, toluene, diethyl ether, and dichloromethane were 
commercially available from Aldrich. Technical grade solvents used for extraction and column 
chromatography were distilled prior to use. Absolute solvents were purchased from Fluka or 
Aldrich in septum sealed bottles. Deuterated solvents were purchased from Cambridge Isotope 
Laboratories. Other materials and reagents were purchased from Fluka, Aldrich, Acros, 
Fluorochem, Boron Molecular, Frontier Scientific, Matrix Scientific or Activate-Scientific in the 
highest available grade and used without further purification.  
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